Curriculum vitae Revised: January 2018
Todd A. Lee, PharmD, PhD
1. GENERAL INFORMATION
A. Personal Data
Work Address:
Department of Pharmacy Systems, Outcomes and Policy (MC 871)
College of Pharmacy
University of Illinois at Chicago
833 South Wood Street
Chicago, IL, 60612
P: 312-355-5140
F: 312-996-0424
email: [email protected]
skype: todd.a..lee
Citizenship: USA
B. Current Positions
Professor and Interim Head
Department of Pharmacy Systems, Outcomes and Policy
College of Pharmacy
University of Illinois at Chicago
Chicago, IL
C. Education
1997 PharmD Pharmacy College of Pharmacy
Drake University
Des Moines, IA
2001 PhD Pharmaceutical Outcomes Research Department of Pharmacy
Pharmacoeconomics University of Washington
Seattle, WA
D. Licensure
1997 – 2016 Washington State Registered Pharmacist
E. Honors and Awards
1991-1996 Drake University Trustee Scholarship
1995-1997 Iowa Pharmacists Association Scholarship
1996-1997 Iowa Graduate Assistant Scholarship
1997 Award for Excellence in the Prescription Laboratory from Merck and Company
1997-1998 American Foundation for Pharmaceutical Education (AFPE) First Year Graduate
Scholarship
1997-1999 Achievement Rewards for College Scientists (ARCS) Fellowship
1997-1999 Eli Lilly Graduate Fellowship in Pharmaceutical Outcomes
1999 Best Contributed Poster Presentation – Student International Society for
Pharmacoeconomics and Outcomes Research (ISPOR) 4th Annual International Meeting
1999-2001 American Foundation for Pharmaceutical Education (AFPE) – Pre-Doctoral Fellowship
2000 AstraZeneca Managed Care Graduate Fellowship
Lee TA, Page 2
Revised: January 2018
2003 American Foundation for Pharmaceutical Education (AFPE) Scholar and Fellow
2005 Center Director’s Award, Midwest Center for Health Services and Policy Research
2007 International Society for Pharmacoeconomics and Outcomes Research (ISPOR) Bernie J.
O’Brien New Investigator Award
2010-2012 Institute for Health Research and Policy (IHRP) Fellow
2013 Best Reviewers, Pharmacoepidemiology and Drug Safety
F. Academic Appointments
2000 Research Fellow
University of Washington, Seattle, WA
Regence Blue Shield, Seattle, WA
Premera Blue Cross, Mountlake Terrace, WA
2001-2008 Adjunct Assistant Professor
Department of Pharmacy Practice
College of Pharmacy
University of Illinois at Chicago
Chicago, IL
2002-2008 Research Assistant Professor
Institute for Healthcare Studies
Division of General Internal Medicine
Department of Medicine
Northwestern University Feinberg School of Medicine
Chicago, IL
2003-2008 Associate Faculty
Center for Pharmacoeconomic Research
College of Pharmacy
University of Illinois at Chicago
Chicago, IL
2004-2010 Affiliate Assistant Professor
Pharmaceutical Outcomes Research and Policy Program
Department of Pharmacy
University of Washington
Seattle, WA
2004-2008 Lecturer
Department of Preventive Medicine
Department of Medicine
Northwestern University Feinberg School of Medicine
Chicago, IL
2008-2009 Assistant Professor
Institute for Healthcare Studies
Division of General Internal Medicine
Department of Medicine
Northwestern University Feinberg School of Medicine
Chicago, IL
2009-2013 Associate Professor
Lee TA, Page 3
Revised: January 2018
Department of Pharmacy Practice
Center for Pharmacoepidemiology and Pharmacoeconomic Research
College of Pharmacy
University of Illinois at Chicago
Chicago, IL
2013-2016 Associate Professor
Department of Pharmacy Systems, Outcomes and Policy
Center for Pharmacoepidemiology and Pharmacoeconomic Research
College of Pharmacy
University of Illinois at Chicago
Chicago, IL
2010-present Departmental Affiliate
Division of Epidemiology and Biostatistics
School of Public Health
University of Illinois at Chicago
Chicago, IL
2010-present Affiliate Faculty
Division of Pulmonary, Critical Care, Sleep and Allergy
Department of Medicine
University of Illinois at Chicago
Chicago, IL
2016-present Professor
Department of Pharmacy Systems, Outcomes and Policy
College of Pharmacy
University of Illinois at Chicago
Chicago, IL
G. Administrative Appointments
2001-2011 Research Scientist, Center for the Management of Complex Chronic Care (CMC3)
Hines VA Hospital, Hines, IL
2007-2008 Director, Northwestern University Health Economic Center, Institute for Healthcare Studies
2007-2011 Director, CMC3 Post-Doctoral Fellowship Program, Hines VA Hospital
2007-2008 Acting Center Co-PI, Center for Management of Complex Chronic Care, Hines VA Hospital
2009-2013 Assistant Director, Center for Pharmacoepidemiology and Pharmacoeconomic Research,
College of Pharmacy, University of Illinois at Chicago
2010-2011 Assistant Director, Center for Management of Complex Chronic Care, Hines VA Hospital
2013-2015 Co-Director, Center for Pharmacoepidemiology and Pharmacoeconomic Research, College
of Pharmacy, University of Illinois at Chicago
2016-present Center Affiliate, Center for Pharmacoepidemiology and Pharmacoeconomic Research,
College of Pharmacy, University of Illinois at Chicago
Lee TA, Page 4
Revised: January 2018
2015-2018 Associate Head for Research, Department of Pharmacy Systems, Outcomes and Policy,
College of Pharmacy, University of Illinois at Chicago
2018-present Interim Head, Department of Pharmacy Systems, Outcomes and Policy, College of
Pharmacy, University of Illinois at Chicago
H. Healthcare Experience
1997-1998 Relief Pharmacist
Swedish Medical Center Home-Care Service
Cameron and Company
Snohomish, WA
1998-1999 Home-Care Pharmacist
Apria Healthcare
Redmond, WA
2. TEACHING
A. Undergraduate or Professional Degree Courses Taught
Pharmacy Law and Ethics, PHARM 543, College of Pharmacy, University of Washington. Teaching
Assistant (4 credit hours). Autumn quarter 1997.
Pharmacotherapeutics I, PHARM 560, College of Pharmacy, University of Washington. Teaching Assistant
(20 lab hours per quarter). Autumn quarter 1997, 1998.
Pharmacotherapeutics II, PHARM 561, College of Pharmacy, University of Washington. Teaching Assistant
(20 lab hours per quarter). Winter quarter 1997, 1998.
Pharmacotherapeutics III, PHARM 562, College of Pharmacy, University of Washington. Teaching Assistant
(20 lab hours per quarter). Spring quarter 1997, 1998.
Pharmacy, Health Care, and Society, PHARM 541, College of Pharmacy, University of Washington. Lecturer
(3 credit hours, 3 lecture hours per quarter). Winter quarter 2000.
Quantitative Methods II, PHARM 479, College of Pharmacy, University of Washington. Teaching Assistant
(3 credit hours, 1.5 lecture hours per quarter, 10 lab discussion hours per quarter). Spring quarter 2001.
Principles of Pharmacoeconomics and Drug Treatment Outcomes, PHAR 356, College of Pharmacy,
University of Illinois at Chicago (2 credit hours, 1 lecture hour 2009, 4 lecture hours 2010). Spring
semester 2009, 2010.
Undergraduate Research, PMPR 380, College of Pharmacy, University of Illinois at Chicago. Instructor
(variable credit hours). Spring 2013.
Roles, Environments, and Communications, PHAR 441, College of Pharmacy, University of Illinois at
Chicago (Course Co-Coordinator, 3 credit hours, 13 lecture hours per semester 2013-2015). Fall semester
2013, 2014, 2015.
Special Projects, PSOP 390, College of Pharmacy, University of Illinois at Chicago. Instructor (variable credit
hours). Fall 2013, 2015.
Lee TA, Page 5
Revised: January 2018
Undergraduate Research, PSOP 380, College of Pharmacy, University of Illinois at Chicago. Instructor
(variable credit hours). Spring semester 2014, Summer term 2017.
Pharmacy and the US Healthcare System, PHAR 461, College of Pharmacy, University of Illinois at Chicago
(Course Co-Coordinator, 2 credit hours). Spring semester 2017
B. Graduate Level Courses Taught
Health Economics and Healthcare Financing, PUB HLTH 433, Department of Preventive Medicine,
Northwestern University Feinberg School of Medicine. Course Coordinator (3 credit hours, 12-15 lecture
hours per quarter). Fall quarter 2004, 2005, 2006, 2007, 2008.
Design of Clinical Trials, BSTT 430, School of Public Health, University of Illinois at Chicago, Instructor
(3 credit hours, 1.5 lecture hours per semester). Spring semester 2003, 2004, 2005.
Advanced Methods and Grant Writing in Health Outcomes Research, PMAD 579, College of Pharmacy,
University of Illinois at Chicago. Instructor (3 credit hours, 6 lecture hours per semester). Spring semester
2006, 2008, 2010.
Pharmacoepidemiology, EPID/PSOP 426, School of Public Health and Department of Pharmacy, Systems,
Outcomes and Policy, University of Illinois at Chicago. Course Coordinator (3 credit hours, 40 lecture
hours per semester). Summer Session I 2010, Spring semester 2013, 2014, 2015, 2016.
Pharmacoepidemiology, PSOP/EPID 526, Department of Pharmacy, Systems, Outcomes and Policy and
School of Public Health, University of Illinois at Chicago. Course Coordinator (3 credit hours, 40 lecture
hours per semester). Spring semester 2017.
Advanced Pharmacoepidemiology Journal Club, PSOP 594, College of Pharmacy, University of Illinois at
Chicago. Course Coordinator (2 credit hours). Fall semester 2015, 2016, 2017; Spring semester 2016,
2017.
PhD Thesis, IPHS 599, School of Public Health, University of Illinois at Chicago. Instructor (variable credit
hours). Fall semester 2011; Spring semester 2012
Independent Study, PSOP 596, College of Pharmacy, University of Illinois at Chicago. Instructor (variable
credit hours). Fall semester 2013, 2014, 2015, 2016, 2017; Spring semester 2013, 2014, 2015, 2016,
2017; Summer term 2015.
Independent Research, PSOP 597, College of Pharmacy, University of Illinois at Chicago. Instructor (variable
credit hours). Spring semester 2014.
PhD Thesis, PSOP 599, College of Pharmacy, University of Illinois at Chicago. Instructor (variable credit
hours). Fall semester 2015, 2016, 2017; Spring semester 2015, 2016, 2017; Summer semester 2015, 2016.
3. PUBLICATIONS
A. Productivity Metrics
H-Index (Scopus)1: 36
Total Citations (Scopus)1: 5873
H-Index (Google Scholar)2: 42
1 From Scopus, last updated June 22, 2017 2 From Google Scholar, last updated August 23, 2017
Lee TA, Page 6
Revised: January 2018
i10-index3: 115
i10-index, since 20123: 98
B. Manuscripts*,†,4
Original Research in Peer-Reviewed Journals
1999
1. Lee TA†, Larson LN. Evaluating the use and the quality of pharmacy drive-up services. J Am Pharm
Assoc. 1999; 39: 338-345. [Cites: 3]
2001
2. Hazlet TK†, Lee TA, Hansten PD, Horn JR. Performance of community pharmacy drug interaction
software. J Am Pharm Assoc. 2001; 41(2): 200-204. [Cites: 96]
3. Lee TA†, Sullivan SD, Veenstra DL, Ramsey SD, Steger PJK, Malinverni R, Pleil AM, Williamson T.
Economic evaluation of systemic treatments for cytomegalovirus retinitis in AIDS patients.
Pharmacoeconomics. 2001; 19(5 Pt 2): 535-550. [Cites: 8]
2003
4. Lee TA†, Hollingworth W, Sullivan SD. Comparison of directly elicited preferences to preferences
derived from the SF-36 in adult asthmatics. Med Decis Making. 2003; 23(4): 323-334. [Cites: 25]
2004
5. Lee TA†, Weiss KB. Fracture risk associated with inhaled corticosteroid use in chronic obstructive
pulmonary disease. Am J Respir Crit Care Med. 2004; 169(7): 855-859. [Cites: 75]
6. Marceille JR†, Goins JA, Soni R, Biery JC, Lee TA. Chronic heart failure-related interventions in
patients receiving rosiglitazone and insulin. Pharmacotherapy. 2004; 24(10): 1317-1322. [Cites: 18]
7. Lee TA†, Veenstra DL, Iloeje UH, Sullivan SD. Cost of chronic hepatitis B infection in the United
States. J Clin Gastroenterol. 2004; 38(10 Suppl 3); S144-S147. [Cites: 36]
2005
8. Lee TA†, Hacek DM, Stroupe KT, Collins SM, Peterson LR. Three surveillance strategies for
vancomycin-resistant enterococci in hospitalized patients: detection of colonization and a cost-
effectiveness model. Infect Control Hosp Epidemiol. 2005; 26(1): 39-46. [Cites: 17]
9. Chiou CF†, Weaver MR, Bell MA, Lee TA, Krieger JW. Development of a multi-attribute pediatric
asthma health outcome measure (PAHOM). Int J Qual Health Care. 2005; 17(1): 23-30. [Cites: 25]
10. Pickard AS†, Wang Z, Walton SM, Lee TA. Are decisions using cost-utility analyses robust to choice
of SF-36/SF-12 preference-based algorithm? Health Qual Life Outcomes. 2005; 3(11). [Cites: 44]
11. Sullivan SD†, Lee TA, Blough DK, Finkelstein JA, Lozano P, Inui TC, Fuhlbrigge AL, Carey VJ,
Wagner E, Weiss KB. A multi-site randomized trial of the effects of physician education and
3 i10-index (number of publications with at least 10 citations) and i10-index since 2012 from Google Scholar, last
updated August 23, 2017 * Denotes trainee, fellow or mentee of Dr. Lee at the time of the publication † Corresponding author 4 Numbers in brackets denote number of citations [cites: ] (from Scopus on June 23, 2017)
Lee TA, Page 7
Revised: January 2018
organizational change in chronic asthma care: Cost-effectiveness analysis of the Pediatric Asthma Care
PORT. Arch Pediatr Adolesc Med. 2005; 159(5): 428-434. [Cites: 45]
12. Buist AS†, Vollmer WM, Sullivan SD, Weiss KB, Lee TA, Menezes AMB, Crapo RO, Jensen RL,
Burney PGJ. The burden of obstructive lung disease initiative (BOLD): rationale and design. COPD.
2005; 2(2): 277-283. [Cites: 173]
13. Lee TA, Wolozin B†, Weiss KB, Bednar MM. Assessment of the emergence of Alzheimer’s disease
following coronary artery bypass graft surgery or percutaneous transluminal coronary angioplasty. J
Alzheimers Dis. 2005; 7(4): 319-324. [Cites: 103]
2006
14. Lee TA†, Bartle B, Weiss KB. Spirometry use in clinical practice following diagnosis of COPD. Chest.
2006; 129(6): 1509-1515. [Cites: 80]
15. Valenstein M†, Ganoczy D, McCarthy JF, Kim HM, Lee TA, Blow FC. Antipsychotic adherence over
time among patients receiving treatment for schizophrenia: a retrospective review. J Clin Psychiatry.
2006; 67(10): 1542-1550. [Cites: 138]
2007
16. Lee TA†, Bartle B, Weiss KB. Impact of NSAIDs on mortality and the effect of pre-existing coronary
artery disease. Am J Med. 2007; 120(1): 98.e9-98.e16. [Cites: 20]
17. Lee TA†, Weaver FM, Weiss KB. The impact of pnuemococcal vaccination on pneumonia rates in
patients with COPD and asthma. J Gen Intern Med. 2007; 22(1): 62-67. [Cites: 44]
18. Lee TA†, Fuhlbrigge AL, Sullivan SD, Finkelstein JA, Inui TS, Lozano P, Weiss KB. Agreement
between caregiver reported healthcare utilization and administrative data for children with asthma. J
Asthma. 2007; 44(3): 189-194. [Cites: 8]
19. Lee TA†, Pickard AS, Bartle B, Weiss KB. Osteoarthritis: a comorbid marker for longer life? Ann
Epidemiol. 2007; 17(5): 380-384. [Cites: 13]
20. Lee TA†, Pickard AS. Meta-analysis of azelastine nasal spray in the treatment of allergic rhinitis.
Pharmacotherapy. 2007; 27(6): 852-859. [Cites: 27]
21. Woltman EM†, Valenstein M, Welsh D, Lee TA, Grabowski J, Reilly PA, Wolschon PA. Using
pharmacy data to inform clinical care: identify partially adherent patients with serious mental illness for
intervention efforts. Psychiatr Serv. 2007; 58(6): 864-867. [Cites: 25]
22. Wolozin B†, Wang SW, Li NC, Lee A, Lee TA, Kazis LE. Simvastatin is associated with a reduced
incidence of dementia and Parkinson’s disease. BMC Medicine. 2007; 5: 20. [Cites: 199]
23. Buist AS†, McBurnie MA, Vollmer WM, Gillespie S, Burney P, Mannino DM, Menezes AM, Sullivan
SD, Lee TA, Weiss KB, Jensen RL, Marks GB, Gulsvik A, Nizankowska-Mogilnicka E for the BOLD
Collaborative Research Group. International variation in the prevalence of chronic obstructive
pulmonary disease: the BOLD study. Lancet. 2007; 370(9589): 741-750. [Cites: 1083]
24. Jordan N†, Lee TA, Valenstein M, Weiss KB. Effect of care setting on evidence-based depression
treatment for veterans with COPD and co-morbid depression. J Gen Intern Med. 2007; 22(10): 1447-
1452. [Cites: 18]
Lee TA, Page 8
Revised: January 2018
25. Joo M*†, Lee TA, Bartle B, Weiss KB. Geographic variation in chronic obstructive pulmonary disease
exacerbation rates. J Gen Intern Med. 2007; 22(11); 1560-1565. [Cites: 17]
26. Stroupe KT†, Smith BM, Lee TA, Tarlov E, Durazo-Arvizu R, Cao L, Nydam T, Huo Z, Burk M,
Cunningham F, Hynes DM, Weiss KB. Effect of increased copayments on pharmacy use in the
Department of Veterans Affairs. Med Care. 2007; 45(11): 1090-1097. [Cites: 17]
27. Lee TA†, Shields AE, Vogeli C, Gibson TB, Sohn MW, Marder WD, Blumenthal D, Weiss KB.
Mortality rates in veterans with multiple chronic conditions. J Gen Intern Med. 2007; 22 Suppl 3: 403-
407. [Cites: 67]
28. Murthy K*†, Grobman WA, Lee TA, Holl JL. Association between rising professional liability
insurance premiums and primary cesarean delivery. Obstet Gynecol. 2007; 110(6): 1264-1269. [Cites:
47]
2008
29. Khare RK*†, Courtney DM, Powell ES, Lee TA. Sixty-four slice computed tomography of the coronary
arteries: cost-effectiveness analysis of patients presenting to the ED with low risk chest pain. Ann
Emerg Med. 2008; 15: 623-632. [Cites: 49]
30. Joo M*†, Lee TA, Weiss KB. Geographic variation in spirometry use in newly diagnosed COPD.
Chest. 2008; 134(1): 38-45. [Cites: 43]
31. Pickard AS†, Wilke CT*, Jung E, Patel S, Lee TA. Use of a preference-based measure of health (EQ-
5D) in COPD and asthma. Resp Med. 2008; 102(4): 519-536. [Cites: 51]
32. Murthy K*†, Grobman WA, Lee TA, Holl JL. Racial disparities in term induction of labor rates in
Illinois. Med Care. 2008; 46(9): 900-904. [Cites: 7]
33. Lee TA†, Pickard AS, Au DH, Bartle B, Weiss KB. Risk for death associated with medications for
recently diagnosed chronic obstructive pulmonary disease. Ann Intern Med. 2008; 149(6): 380-390.
[Cites: 153]
34. Joo M*†, Lee TA, Bartle B, van de Graaff W, Weiss KB. Patterns of healthcare utilization by COPD
severity: a pilot study. Lung. 2008; 186(5): 307-312. [Cites: 12]
35. Stuck RM†, Sohn MW, Budiman-Mak E, Lee TA, Weiss KB. Charcot arthropathy risk elevation in the
obese diabetic population. Am J Med. 2008; 121: 1008-1014. [Cites: 35]
36. Joo MJ*†, Lee TA, Au DH, Fitzgibbon ML, Weiss KB. Medication use patterns associated with
spirometry in diagnosing COPD. COPD. 2008; 5(6): 360-368. [Cites: 10]
2009
37. Pickard AS†, Jung E, Bartle B, Weiss KB, Lee TA. Coded cause of death and timing of COPD
diagnosis. COPD. 2009; 6(1): 41-47. [Cites: 1]
38. Jordan N†, Lee TA, Valenstein M, Pirraglia PA, Weiss KB. Effect of depression care on outcomes in
COPD patients with depression. Chest. 2009; 135(3): 626-632. [Cites: 16]
39. Jung E, Pickard AS†, Salmon JW, Bartle B, Lee TA. Medication adherence and persistence in the last
year of life in COPD patients. Resp Med. 2009; 103(4): 525-534. [Cites: 27]
Lee TA, Page 9
Revised: January 2018
40. Murthy K*†, Grobman WA, Lee TA, Holl JL. Obstetricians’ rising liability insurance premiums and
inductions at late preterm gestations. Med Care. 2009; 47(4): 425-430. [Cites: 14]
41. Scheetz MH†, Bolon MK, Postelnick M, Noskin GA, Lee TA. Cost effectiveness analysis of an
antimicrobial stewardship team on blood stream infections: a probabilistic analysis. J Antimicrob
Chemother. 2009; 63(4): 816-825. [Cites: 36]
42. Sohn MW†, Lee TA, Stuck RM, Frykberg R, Budiman-Mak E. Mortality risk of Charcot arthropathy
compared to diabetic foot ulcer and diabetes alone. Diab Care. 2009; 32(5): 816-821. [Cites: 50]
43. Lee TA†, Wilke CT*, Joo M*, Stroupe KT, Krishnan J, Schumock GT, Pickard AS. Outcomes
associated with tiotropium use in COPD patients. Arch Intern Med. 2009; 169(15): 1403-1410. [Cites:
39]
44. Lee TA†, Pickard AS, Bartle B, Schumock GT. Mortality risk in patients receiving drug regimens with
theophylline for chronic obstructive pulmonary disease. Pharmacotherapy. 2009; 29(9): 1039-1053.
[Cites: 20]
45. Gibson TB†, Lee TA, Vogeli CS, Hidalgo J, Carls GS, Sredl K, DesHarnais S, Marder WD, Weiss KB,
Williams TV, Shields AE. A four-system comparison of patients with chronic illness: the Military
Health System, Veterans Health Administration, Medicaid, and commercial plans. Mil Med. 2009;
174(9): 936-943. [Cites: 12]
46. Pickard AS†, Shaw JW, Lin HW, Trask P, Aaronson N, Lee TA, Cella D. A patient-based utility
measure of health for clinical trials of cancer therapy based on the European Organization for the
Research and Treatment of Cancer Quality of Life Questionnaire. Value Health. 2009; 12(6): 977-988.
[Cites: 17]
47. Nielsen R†, Johannessen A, Benediktsdottir B, Gislason T, Buist AS, Gulsvik A, Sullivan SD, Lee TA.
Present and future costs of COPD in Iceland and Norway: Results from the BOLD study. Eur Respir J.
2009; 34(4): 850-857. [Cites: 57]
48. Braddy KK†, Imam, SN, Palla KR, Lee TA. Vitamin D deficiency/insufficiency practice patterns in a
Veterans Administration long-term care population: a retrospective analysis. J Am Med Dir Assoc.
2009; 10(9): 653-657. [Cites: 47]
2010
49. Wilke CT*, Pickard AS†, Walton SM, Moock J, Kohlman T, Lee TA. Statistical implications of utility
weighted and equally weighted HRQL measures: an empirical study. Health Econ. 2010; 19(1): 101-
110. [Cites: 7]
50. Sohn MW†, Stuck RM, Pinzur M, Lee TA, Budiman-Mak E. Lower extremity amputation risk
following Charcot arthropathy and diabetic foot ulcer. Diab Care. 2010; 33(1): 98-100. [Cites: 68]
51. Ogale SS*, Lee TA†, Au DH, Boudreau DM, Sullivan SD. Cardiovascular events associated with
ipratropium bromide in COPD. Chest. 2010; 137(1): 13-19. [Cites: 49]
52. Joo MJ*†, Au DH, Fitzgibbon ML, Lee TA. Inhaled corticosteroids and risk of pneumonia in newly
diagnosed COPD. Respir Med. 2010; 104(2): 246-252. [Cites: 38]
Lee TA, Page 10
Revised: January 2018
53. Evans CT†, Li K, Burns SP, Smith B, Lee TA, Weaver FM. Antibiotic prescribing for acute respiratory
infection and subsequent outpatient and hospital utilization in veterans with spinal cord injury and
disorder. PM& R. 2010; 2(2): 101-109. [Cites: 5]
54. Hynes D†, Tarlov E, Durazo-Arvizu R, Perrin R, Zhang Q, Weichle T, Ferriera M, Lee TA, Benson A,
Bhoopalam N, Bennett C. Surgery and adjuvant chemotherapy use among veterans with colon cancer:
insights from a California study. J Clin Oncol. 2010; 28(15): 2571-2576. [Cites: 8]
55. Stein BD, Charbeneau JT, Lee TA, Schumock GT, Lindenauer PK, Bautista A, Naureckas ET,
Krishnan JA†. Hospitalizations for acute exacerbations of chronic obstructive pulmonary disease: how
you count matters. COPD. 2010; 7(3): 164-171. [Cites: 20]
56. Brennan NJ, Lee TA†, Wilk AS, Lyttle CS, Weiss KB. Defining an episode of care for colonoscopy:
work of the high value health care project characterizing episodes and costs of care. Gastrointest
Endosc Clin N Am. 2010; 20(4): 735-750. [Cites: 1]
57. Sohn MW†, Budiman-Mak E. Stuck RM, Siddiqui F, Lee TA. Diagnostic accuracy of existing methods
for identifying diabetic foot ulcers from inpatient and outpatient datasets. J Foot Ankle Res. 2010; 3:
27. [Cites: 11]
58. Lee TA†, Chang CL, Stephenson JJ, Sajjan SG, Maiese EM, Everett S, Allen-Ramey F. Impact of
asthma controller medications on medical and economic resource utilization in adult asthma patients.
Curr Med Res Opin. 2010; 26(12): 2851-2860. [Cites: 11]
2011
59. Cooke CR†, Joo MJ*, Anderson SM, Lee TA, Udris EM, Johnson E, Au DH. The validity of using
ICD-9 codes and pharmacy records to identify patients with chronic obstructive pulmonary disease.
BMC Health Serv Res. 2011; 11:37. [Cites: 44]
60. Schumock GT†, Walton SM, Lee TA, Marx SE, Audhya P, Andress DL. Comparative effectiveness of
paricalcitol versus cinacalcet for secondary hyperparathyroidism in patients receiving hemodialysis.
Nephron Clin Pract. 2011; 117(2): c151-c159. [Cites: 6]
61. Pickard AS†, Yang Y, Lee TA. Comparison of health-related quality of life measures in chronic
obstructive pulmonary disease. Health Qual Life Outcomes. 2011; 9(1): 26. [Cites: 46]
62. Sohn MW†, Budiman-Mak E, Lee TA, Oh E, Stuck RM. Significant J-shaped association between
body mass index (BMI) and diabetic foot ulcers. Diabetes Metab Res Rev. 2011; 27(4): 402-409.
[Cites: 14]
63. Murthy K*†, Grobman WA, Lee TA, Holl JL. Trends in induction of labor at early-term gestation. Am J
Obstet Gynecol. 2011; 204(5): 435.e1-36. [Cites: 22]
64. Morden NE†, Sullivan SD, Bartle B, Lee TA. Skeletal health in men with chronic lung disease: rates of
testing, treatment and fractures. Osteoporos Int. 2011; 22(6): 1855-1862. [Cites: 11]
65. Schumock GT†, Lee TA, Joo MJ*, Valuck RJ, Stayner LT, Gibbons RD. Association between
leukotriene-modifying agents and suicide: what is the evidence? Drug Safety. 2011; 34(7): 533-544.
[Cites: 18]
Lee TA, Page 11
Revised: January 2018
66. Scheetz MH†, Bolon MK, Esterly JS, Reddy P, Postelnick M, Lee TA. Life-years gained with
meropenem over ciprofloxacin in penicillin-allergic patients with gram-negative bacilli sepsis: results
of a probabilistic model. Pharmacotherapy. 2011; 31(5): 469-479. [Cites: 1]
67. Schumock GT†, Gibbons RD, Lee TA, Joo MJ*, Valuck RJ, Stayner LT. Relationship between
leukotriene-modifying agent prescriptions dispensed and rate of suicide deaths by county in the US.
Drug Healthc Patient Saf. 2011; 3: 47-57. [Cites: 8]
68. Murthy K*†, Holl JL, Lee TA, Grobman WA. National trends and racial differences in late preterm
induction. Am J Obstet Gynecol. 2011; 205(5): 458.e1-7. [Cites: 9]
69. Joo MJ*†, Au DH, Fitzgibbon ML, McKell J, Lee TL. Determinants of spirometry use and accuracy of
COPD diagnosis in primary care. J Gen Intern Med. 2011; 26(11): 1272-1277. [Cites: 21]
70. Pickard AS†, Lee TA, Solem CT*, Joo MJ*, Schumock GT, Krishnan JA. Prioritizing comparative-
effectiveness research topics via stakeholder involvement: an application in COPD. Clin Pharmacol
Ther. 2011; 90(6): 888-892. [Cites: 8]
71. Valenstein M†, Kavanagh J, Lee TA, Reilly P, Dalack GW, Grabowski J, Smelson D, Ronis D,
Ganoczy D, Woltmann E, Metreger T, Wolschon P, Jensen A, Poddig B, Blow FC. Using a pharmacy-
based intervention to improve antipsychotic adherence among patients with serious mental illness.
Schizophr Bull. 2011; 37(4): 727-736. [Cites: 37]
2012
72. Schumock GT†, Gibbons RD, Lee TA, Joo MJ*, Stayner LT, Valuck RJ. The association between
leukotriene-modifying agents and spontaneously reported suicide. Drug Information Journal. 2012;
46(1): 99-106. [Cites: 2]
73. Stein BD, Bautista A, Schumock GT, Lee TA, Charbeneau JT, Lauderdale DS, Naureckas ET, Meltzer
DO, Krishnan JA†. The validity of ICD-9-CM diagnosis codes for identifying patients hospitalized for
COPD exacerbations. Chest. 2012; 141(1): 87-93. [Cites: 47]
74. Solem CT*, Lee TA, Joo MJ*, Lambert BL, Walton SM, Pickard AS†. Complexity of medication use in
newly diagnosed COPD patients. Am J Geriatr Pharmacother. 2012; 10(2): 110-122. [Cites: 8]
75. Santayana EM, Grim SA, Janda WM, Layden JE, Lee TA, Clark NM. Risk factors and outcomes
associated with vancomycin-resistant Enterococcus (VRE) infections with reduced susceptibility to
linezolid. Diagn Microbiol Infect Dis. 2012; 74(1): 39-42. [Cites: 8]
76. Schumock GT†, Stayner LT, Valuck RJ, Joo MJ*, Gibbons RD, Lee TA. Risk of suicide attempt in
asthmatic children and young adults prescribed leukotriene-modifying agents: a nested case-control
study. J Allergy Clin Immunol. 2012; 130(2): 368-375. [Cites: 17]
77. Tarlov E†, Stroupe KT, Lee TA, Weichle TW, Zhang QL, Michaelis LC, Ozer H, Browning MM,
Hynes DM. Trends in anemia management in lung and colon cancer patients in the US Department of
Veterans Affairs, 2002-2008. Support Care Cancer. 2012; 20(8): 1649-1657. [Cites: 6]
78. Patterson BW†, Khare RK*, Courtney M, Lee TA, Kyriacou DN. Cost-effectiveness of influenza
vaccination of older adults in the emergency department setting. Am J Emerg Med. 2012; 30(7): 1072-
1079. [Cites: 4]
Lee TA, Page 12
Revised: January 2018
79. Stroupe KT†, Tarlov E, Lee TA, Weichle TW, Zhang QL, Michaelis LC, Ozer H, Browning MM,
Hynes DM. Hemoglobin levels triggering erythropoiesis-stimulating agent therapy in cancer patients
following FDA policy change. Pharamcotherapy. 2012; 32(11): 988-997. [Cites: 3]
80. Tarlov E†, Lee TA, Weichle TW, Durazo-Arvizu R, Zhang Q, Perrin R, Bentrem D, Hynes DM.
Reduced overall and event-free survival among colon cancer patients using dual system care. Cancer
Epidemiol Biomarkers Prev. 2012; 21(12): 2231-2241. [Cites: 9]
81. Schnell K, Weiss CO, Lee TA, Krishnan JA, Leff B, Wolff JL, Boyd C. The prevalence of clinically-
relevant comorbid conditions in patients with physician-diagnosed COPD: a cross-sectional study using
data from NHANES 1999-2008. BMC Pulm Med. 2012; 12:26. [Cites: 86]
2013
82. Krishnan JA, Lindenauer PK, Au DH, Carson SS, Lee TA, McBurnie MA, Naureckas ET, Vollmer
WM, Mularski RA. Stakeholder priorities for comparative effectiveness research in COPD: a workshop
report. Am J Respir Crit Care Med. 2013; 187(3): 320-326. [Cites: 20]
83. Joo MJ†, Sharp LK, Au DH, Lee TA, Fitzgibbon ML. Use of spirometry in the diagnosis of COPD: a
qualitative study in primary care. COPD. 2013; 10(4): 444-449. [Cites: 11]
84. Stroupe KT†, Smith BM, Hogan TP, St. Andre JR, Gellad WF, Weiner S, Lee TA, Burk M,
Cunningham F, Piette JD, Rogers TJ, Huo Z, Weaver FM. Medication acquisition across systems of
care and patient-provider communication among older veterans. Am J Health-Syst Pharm. 2013; 70:
804-813. [Cites: 7]
85. Brahmbhatt M, Palla K, Kossifologos A, Mitchell D, Lee T. Appropriateness of medication prescribing
using the STOPP/START criteria in veterans receiving home-based primary care. Consult Pharm.
2013; 28(6): 361-369. [Cites: 3]
86. Carbone LD†, Chin AS, Lee TA, Burns SP, Svircev JN, Hoenig HM, Akhigbe T, Weaver FM. The
association of opioid use with incident lower extremity fractures in spinal cord injury. J Spinal Cord
Med. 2013; 36(2): 91-96. [Cites: 8]
87. Lindenauer PK†, Grosso LM, Wang C, Wang Y, Krishnan JK, Lee TA, Au DH, Mularski RA,
Bernheim SM, Drye EE. Development, validation and results of a risk-standardized measure of hospital
30-day mortality for patients with exacerbation of COPD. J Hosp Med. 2013; 8: 428-435. [Cites: 6]
88. Carbone L, Chin AS, Lee TA, Burns SP, Svircev JN, Hoenig H, Akhigbe T, Thomas F, Bailey L,
Weaver F. The association of anticonvulsant use with fractures in spinal cord injury. Am J Phys Med
Rehabil. 2013; 92(12): 1037-1046. [Cites: 4]
89. Sohn MW†, Meadows JL, Oh EH, Budiman-Mak E, Lee TA, Stone NJ, Pearce WB. Statin use and
lower-extremity amputation risk in non-elderly diabetic patients. J Vasc Surg. 2013; 58(6): 1578-1585.
[Cites: 11]
90. Lin FJ*, Lee TA, Wong PS, Pickard AS†. Evaluation of changes in guidelines for medication
management of stable chronic obstructive pulmonary disease. J Eval Clin Pract. 2013; 19(5): 953-960.
[Cites: 2]
2014
Lee TA, Page 13
Revised: January 2018
91. Jordan N†, Sohn MW, Bartle B, Valenstein M, Lee Y, Lee TA. Association between chronic illness
complexity and receipt of evidence-based depression care. Med Care. 2014; 52 Suppl 3: S126-S131.
[Cites: 3]
92. Sumino K*, O’Brian K, Bartle B, Au DH, Castro M, Lee TA. Coexisting chronic conditions associated
with mortality and morbidity in adult patients with asthma. J Asthma. 2014; 51(3): 306-314. [Cites: 17]
93. Suda KJ, Regen SM, Lee TA, Easterling JL, Hunklwer RJ, Danziger LH. Outpatient influenza antiviral
prescription trends with influenza-like illness in the USA, 2008-2010. Int J Antimicrob Agents. 2014;
43(3): 279-283. [Cites: 2]
94. Dilokthornsakul P*, Chaiyakunapruk N, Schumock GT, Lee TA†. Calendar time-specific propensity
score analysis for observational data: a case study estimating the effectiveness of inhaled long-acting
beta-agonist on asthma exacerbations. Pharmacoepidemiol Drug Safety. 2014; 23(2): 152-164. [Cites:
3]
95. Adimadhyam S*, Schumock GT, Walton S, Joo M, McKell J*, Lee TA†. Risk of arrhythmias associated
with ipratropium bromide in children, adolescents and young adults with asthma: a nested case-control
study. Pharmacotherapy. 2014; 34(4): 315-323. [Cites: 2]
96. Carbone L†, Chin AS, Lee TA, Burns SP, Svircev JN, Hoenig HM, Bailey L, Weaver FM. Thiazide
use is associated with reduced risk for incident lower extremity fractures in men with spinal cord
injury. Am J Phys Med Rehabil. 2014; 95(6): 1015-1020. [Cites: 2]
97. Garg N, Rolle AJ, Lee TA, Prasad B*. Home-based diagnosis of obstructive sleep apnea in an urban
population. J Clin Sleep Med. 2014; 10(8): 879-885. [Cites: 9]
98. Lin FJ*, Pickard AS, Krishnan JK, Joo MJ, Au DH, Carson SS, Gillespie S, Henderson AG, Lindenauer
PK, McBurnie MA, Mularski RA, Naurekas ET, Vollmer WM, Lee TA; CONCERT Consortium.
Measuring health-related quality of life in chronic obstructive pulmonary disease: properties of the EQ-
5D-5L and PROMIS-43 short form. BMC Med Res Methodol. 2014; 14:78. [Cites: 12]
99. Cannon J, Lee TA, Clark N, Setlak P, Grim S. The risk of seizures among the carbapenems: a meta-
analysis. J Antimicrob Chemother. 2014; 69(8): 2043-2055. [Cites: 21]
100. Prentice JC, Conlin PR, Gellad WF, Edelman D, Lee TA, Pizer SD. Capitalizing on prescribing pattern
variation to compare medications for type 2 diabetes. Value Health 2014; 17(8): 854-862. [Cites: 10]
101. Dilokthornsakul P*, Chaiyakunapruk N, Nimpitakpong P, Jeanperrapong N, Jampachaisri K, Lee TA.
Understanding medication oversupply and its predictors in the outpatient departments in Thailand.
BMC Health Serv Res 2014; 14:408. [Cites: 1]
102. Prieto-Centurion V, Rolle AJ, Au DH, Carson SS, Henderson AG, Lee TA, Lindenauer PK, McBurnie
MA, Mularski RA, Naureckas ET, Vollmer WM, Joese BJ, Krishnan JA, CONCERT Consortium.
Multicenter study comparing case definitions used to identify patients with chronic obstructive
pulmonary disease. Am J Respir Crit Care Med 2014; 190(9): 989-995. [Cites: 12]
103. Zueger PM*, Schultz NM, Lee TA. Cost effectiveness of liraglutide in type II diabetes: a systematic
review. Pharmacoeconomics. 2014; 32(11): 1079-1091. [Cites: 5]
104. Lee WJ, Lee TA, Pickard AS, Caskey RN, Schumock GT†. Drugs associated with adverse events in
children and adolescents. Pharmacotherapy. 2014; 34(9): 918-926. [Cites: 7]
Lee TA, Page 14
Revised: January 2018
105. Qato DM†, Daviglus ML, Wilder J, Lee T, Qato D, Lambert B. ‘Pharmacy deserts’ are prevalent in
Chicago’s predominantly minority communities, raising medication access concerns. Health Aff
(Millwood); 2014; 33(11): 1958-1965. [Cites: 3]
106. Patel UC†, McKissic EL, Kasper D, Lentino JR, Pachucki CT, Lee T, Lopansri BK. Outcomes of
ceftriaxone use compared to standard of therapy in methicillin susceptible staphylococcal aureus
(MSSA) bloodstream infections. Int J Clin Pharm. 2014; 36(6): 1282-1289. [Cites: 1]
2015
107. Ursan ID, Jiang R, Pickard EM, Lee TA, Ng D, Pickard AS†. Emergence of BCR-ABL kinase domain
mutations associated with newly diagnosed chronic myeloid leukemia: a meta-analysis of clinical trials
of tyrosine kinase inhibitors. J Manag Care Spec Pharm. 2015; 21(2): 114-122. [Cites: 6]
108. Prentice JC, Conlin PR, Gellad WF, Edelman D, Lee TA, Pizer SD. Long-term outcomes of analogue
insulin compared with NPH for patients with type 2 diabetes mellitus. Am J Manag Care. 2015; 21(3):
e235-e243. [Cites: 0]
109. Lee WJ, Lee TA, Pickard AS, Shoaibi A, Schumock GT†. Using linked electronic data to validate
algorithms for health outcomes in administrative databases. J Comp Eff Res. 2015; 4(4): 359-366.
110. Qato DM†, Manzoor BS, Lee TA. Drug-alcohol interactions in older U.S. adults. J Am Geriatr Soc.
2015; 63(11): 2324-2331
2016
111. Stanford RH†, Nag A, Mapel DW, Lee TA, Rosiello R, Vekeman F, Gauthier-Loiselle M, Duh MS,
Merrigan JF, Schatz M. Validation of a new risk measure for chronic obstructive pulmonary disease
exacerbation using health insurance claims data. Ann Am Thorac Soc. 2016; 13(7): 1067-1075.
112. Qato DM†, Lee TA, Durazo-Arvizu R, Wu D, Wilder J, Reina SA, Cai J, Gonzalez F 2nd, Talavera
GA, Ostfeld RJ, Daviglus ML. Statin and aspirin use among Hispanic and Latino adults at high risk for
cardiovascular risk: findings from the Hispanic Community Health Study/Study of Latinos. J Am Heart
Assoc. 2016; 5(4): pii: e002905. [Cites: 1]
113. Fishbein AB†, Lee TA, Oh SS, Eng C, Hu D, Huntsman S, Farber HJ, Serebrisky D, Silverbery J,
Williams LK, Seibold MA, Sen S, Borrell LN, Avila P, Rodriguez-Cintron W, Rodriguez-Santana JR,
Burchard EG, Kumar R. Sensitization to mouse and cockroach allergens and asthma morbidity in urban
minority youth. Genes-environments and admixture in Latino American (GALA-II) and Study of
African-Americans, Asthma, Genes and Environments (SAGE-II). Ann Allergy Asthma Immunol.
2016; 117(1): 43-49. [Cites: 1]
114. Lee WJ, Briars L, Lee TA, Calip GS, Suda KJ, Schumock GT†. Top-down versus step-up prescribing
strategies for tumor necrosis factor alpha inhibitors in children and young adults with inflammatory
bowel disease. Inflamm Bowel Dis. 2016; 22(10): 2410-2417.
115. Dilokthornsakul P*†, Lee TA, Dhippayom T, Jeanpeerapong N, Chaiyakunapruk N. Comparison of
health care utilization and costs for patients with asthma by severity and health insurance in Thailand.
Value Health Reg Issues. 2016; 9: 105-111. [Cites: 2]
116. Lee WJ, Briars L, Lee TA, Calip GS, Suda KJ, Schumock GT†. Use of tumor necrosis factor-alpha
inhibitors in children and young adults with juvenile idiopathic arthritis or rheumatoid arthritis.
Pharmacotherapy. 2016; 36(12): 1201-1209.
Lee TA, Page 15
Revised: January 2018
2017
117. Kim K, Lee TA, Touchette DR, DiDomenico RJ, Ardati, AK, Walton SM†. Contemporary trends in
oral antiplatelet use in patients treated with percutaneous coronary intervention for acute coronary
syndrome. J Manag Care Spec Pharm. 2017; 23(1): 57-63. [Cites: 2]
118. Samp JC*, Joo MJ, Schumock GT, Calip GS, Pickard AS, Lee TA†. Comparative effectiveness of long-
acting β2-agonists combined with a long-acting muscarinic antagonist or inhaled corticosteroid in
chronic obstructive pulmonary disease. Pharmacotherapy. 2017; 37(4): 447-455.
119. Jiang R, Lee I*, Lee TA, Pickard AS†. The societal costs of heroin use disorder in the United States.
PLos One. 2017; 12(5): e0177323.
120. Kim K, Lee TA, Touchette DR, DiDomenico RJ, Ardati AK, Walton SM†. Comparative effectiveness
of oral antiplatelet agents in patients with acute coronary syndrome. Pharmacotherapy. 2017; 37(8):
877-887.
121. Pickard AS†, Hung YT, Lin FJ, Lee TA. Patient experience-based value sets: are they stable? Med
Care. 2017; 55(11): 979-984.
122. Manzoor BS, Lee TA, Sharp L, Walton SM, Galanter WL, Nutescu EA†. Real-world adherence and
persistence with direct oral anticoagulants in adults with atrial fibrillation. Pharmacotherapy. 2017;
37(10): 1221-1230.
123. Samp JC*, Joo MJ, Schumock GT, Calip GS, Pickard AS, Lee TA†. Risk of cardiovascular and
cerebrovascular events in COPD patients treated with long-acting β2-agonist combined with a long-
acting muscarinic or inhaled corticosteroid. Ann Pharmacother. 2017; 51(11): 945-953.
124. Manzoor BS, Walton SM, Sharp LK, Galanter WL, Lee TA, Nutescu EA. High number of newly
initiated direct oral anticoagulant users switch to alternate anticoagulant therapy. J Thromb
Thrombolysis. 2017; 44(4): 435-441.
125. Xing S*†, Lee TA. Increased risk of diabetes among 6-24 years olds using second generation
antipsychotics. J Child Adolesc Psychopharmacol. 2017; 27(9): 782-791.
In Press
126. Lee WJ, Lee TA, Suda KJ, Calip GS, Briars LA, Schumock GT†. Risk of serious bacterial infection
associated with tumor necrosis factor-alpha inhibitors in children with juvenile idiopathic arthritis.
Rheumatology. In Press.
127. Harrington RL*, Adimadhyam S, Lee TA, Schumock GT, Antoon JW†. Oseltamivir and suicide among
pediatric patients. Ann Fam Med. In Press.
128. Samp JC*, Joo MJ, Schumock GT, Calip GS, Pickard AS, Lee TA†. Predicting acute exacerbations in
chronic obstructive pulmonary disease. J Manag Care Pharm. In Press.
129. Lee WJ, Lee TA, Suda KJ, Calip GS, Briars LA, Schumock GT†. Risk of serious bacterial infection
associated with tumor necrosis factor-alpha inhibitors in children and young adults with inflammatory
bowel disease. Inflamm Bowel Dis. In Press.
Lee TA, Page 16
Revised: January 2018
130. Kim K, Lee TA, Touchette DR, DiDomenico RJ, Ardata AK, Walton SM†. Comparison of six-month
costs between oral antiplatelet agents following acute coronary syndrome. J Manag Care Spec Pharm.
In Press.
131. Xing S*, Kim S, Schumock GT, Touchette DR, Calip GS, Loew A, Lee TA†. Risk of diabetes
hospitalization or diabetes drug intensification in patients with depression and diabetes using second
generation antipsychotics compared to other depression therapies. Prim Care Companion CNS Disord.
In Press.
132. Xing S*, Calip GS, Leow AD, Kim S, Schumock GT, Touchette DR, Lee TA†. The impact of
depression medications on oral antidiabetic drug adherence in patients with diabetes and depression. J
Diabetes Complications. In Press.
Review or Non-original Research Articles in Peer-Reviewed Journals
133. Sullivan SD†, Ramsey SD, Lee TA. The economic burden of COPD. Chest. 2000; 117: 5S-9S. [Cites:
411]
134. Lee TA†, Weiss KB. An update on the health economics of asthma and allergy. Curr Opin Allergy Clin
Immunol. 2002; 2: 195-200. [Cites: 8]
135. Lee TA†, Drivers CH, Leibman CW. Evaluating the efficiency of treatment in the allergic rhinitis
market. J Manag Care Pharm. 2004 Jan-Feb; 10(1 Suppl 1): 3-8. [Cites: 5]
136. Reed SD†, Lee TA, McCrory DC. The economic burden of allergic rhinitis: a critical evaluation of the
literature. Pharmacoeconomics. 2004; 22(6): 345-361. [Cites: 151]
137. Cannon JP†, Lee TA, Bolanos JT, Danziger LH. Pathogenic relevance of Lactobacillus: A retrospective
review of over 200 cases. Eur J Clin Microbiol Infect Dis. 2005; 24(1): 31-40. [Cites: 218]
138. Chapman KR†, Mannino DM, Soriano JB, Vermeire PA, Buist AS, Thun MJ, Connell C, Jemel A, Lee
TA, Miravitlles M, Aldington S, Beasly R. Epidemiology and costs of chronic obstructive pulmonary
disease. Eur Respir J. 2006; 27(1): 188-207. [Cites: 431]
139. Vogeli C†, Shields A, Lee TA, Gibson TB, Marder WD, Weiss KB, Blumenthal D. Multiple chronic
conditions: Prevalence and implications for patient management, outcomes and costs. J Gen Intern
Med. 2007; 22 Suppl 3: 391-395. [Cites: 373]
140. Joo MJ*†, Au DH, Lee TA. Use of spirometry in the diagnosis of COPD and efforts to improve quality
of care. Transl Res. 2009; 154(3): 103-110. [Cites: 13]
141. Akinbami LJ, Sullivan SD, Campbell JD, Grundmeier RW, Hartert TV, Lee TA, Smith RA. Asthma
outcomes: Healthcare utilization and costs. J Allergy Clin Immunol. 2012; 129(3 Suppl): S49-S64.
[Cites: 42]
142. Mularski RA, McBurnie MA, Lindenauer PK, Lee TA, Vollmer WM, Au DH, Carson SS, Krishnan
JA. Comparative effectiveness research in chronic obstructive pulmonary disease. J Comp Eff Res.
2012; 1(1): 71-82. [Cites: 5]
143. Lee TA, von Riedemann S, Tricta F. Cost-utility of chelators in transfuction-dependent beta-
thalassemia major patients: a review of the pharmacoeconomic literature. Expert Rev Pharmacoecon
Outcomes Res. 2014; 4(5): 651-660. [Cites: 1]
Lee TA, Page 17
Revised: January 2018
144. Lee TA. Devices made easy: a review of inhaler technique and patient adherence in COPD. Pharmacy
Times. 2015; 81(6). [Cites: 0]
145. Han MLK, Martinez CH, Au DH, Bourbeau J, Boyd CM, Branson R, Criner GJ, Kalhan R, Kallstrom
TJ, King A, Krishnan JA, Lareau SC, Lee TA, Lindell K, Mannino DM, Martinez FJ, Meldrum C,
Press VG, Thomashow B, Tycon L, Sullivan JL, Walsh J, Wilson KC, Wright J, Yawn B, Zueger PM*,
Bhatt SP, Dransfield MT. Meeting the challenges of COPD care delivery in the USA: a multiprovider
perspective. Lancet Respir Med. 2016; 4(6): 473-526. [Cites: 5]
146. Donnelly PC, Sutich R, Easton R, Adejumo O, Lee TA, Logan LK. Ceftriaxone-associated biliary and
cardiopulmonary adverse events in neonates: a systematic review of the literature. Pediatr Drugs.
2017; 19(1): 21-34. [Cites: 2]
147. Law EH, Badowski M, Hung YT, Weems K, Sanchez A, Lee TA. Association between proton pump
inhibitors and microscopic colitis: implications for practice and future research. Ann Pharmacother.
2017; 51(3): 253-263.
Articles in Non-Refereed Journals
148. Lee TA†, Weiss KB. Preference assessment in patients with asthma. Expert Rev Pharmacoeconomics
Outcomes Res. 2002; 2(6): 607-618. [Cites: 4]
149. Rutten-van Mölken M†, Lee TA. Economic modeling in COPD. Proc Am Thorac Soc. 2006; 3(7): 630-
634. [Cites: 24]
C. Letters to the Editor
1. Lee TA, Weiss KB. Inhaled corticosteroids and fracture risk in COPD [letter]. Am J Respir Crit Care
Med. 2004; 170(1): 94-95.
2. Lee TA, Sullivan SD, Weiss KB. Cost-effectiveness of inhaled corticosteroids in COPD [letter]. Am J
Med. 2004; 117(8): 618.
3. Bendar MM, Lee TA, Wolozin B, Weiss KB. Coronary artery bypass grafting is not a risk factor for
dementia or Alzheimer’s disease [letter]. Neurology. 2006; 66(11): 1785.
4. Lee TA, Pickard AS, Au DH. How much did biases in study of chronic obstructive pulmonary disease
medications and mortality affect the outcome [letter]. Ann Intern Med. 2009; 150(6): 426-427.
5. Ogale S, Lee TA, Sullivan SD. Safety of ipratropium bromide [letter]. Chest. 2010; 138(1): 235-236.
6. Sohn MW, Oh EH, Budiman-Mak E, Lee TA, Stone NJ, Pearce WB. Reply [letter]. J Vasc Surg. 2014;
59(3): 876.
7. Law EH, Badowski M, Lee TA. Reply: Association between proton pump inhibitors and microscopic
colitis: implications for practice and future research [letter]. Ann Pharmacother. 2017; 51(8): 719.
D. Dissertation
Lee TA. Comparison of the cost-effectiveness of triamcinolone acetonide (Azmacort HFA) and
fluticasone propionate (Flovent) in adult asthmatics in a randomized controlled equivalence trial.
University of Washington. 2001. Pgs 154. UMI Publication No. AAT 3022859. ISBN 0-493-33719-9.
E. Book Chapters
Lee TA, Page 18
Revised: January 2018
1. Ramsey SD, Lee TA, Sullivan SD. Financial aspects of emphysema and LVRS. In: Lung Volume
Reduction Surgery for Emphysema. Eds. Fessler HE, Reilly JJ, Sugarbaker DJ. New York: Marcel
Dekker; 2003. Pgs. 413-424.
2. Bennett CL, Lee TA. Economic analysis of cancer treatment. In: Clinical Oncology. Eds. Abeloff MD,
Armitage JO, Niederhuber JE, Kastan MB, McKenna WG. Churchill Livingstone; 2004.
3. Sullivan SD, Lee TA, Ogale S. Socioeconomic burden of COPD. In: Long-Term Intervention in
Chronic Obstructive Pulmonary Disease. Eds. Pauwels R, Postma D, Weiss S. Marcel Dekker, Inc.;
2004. Pgs 101-118.
4. Lee TA. Socioeconomic burden of acute asthma exacerbations. In: Exacerbations of Asthma. Eds.
O’Byrne P, Johnston S. Taylor and Francis. 2006. Pgs. 43-56.
5. Lee TA, Pickard AS. Exposure definition and measurement. In: Velentgas P, Dreyer NA, Nourjah P, et
al., eds. Developing a Protocol for Observational Comparative Effectiveness Research: A User’s
Guide. AHRQ Publication No. 12(13)-EHC099. Rockville, MD: Agency for Healthcare Research and
Quality; January 2013: Chapter 4, pp. 45-58
F. Federal Reports / Commissioned Reports 1. Lee TA, Schumock GT, Bartle B, Pickard AS. Mortality risk in chronic obstructive pulmonary disease
patients using theophylline. Effective Health Care Research Report No. 16. (Prepared by Chicago-Area
DEcIDE Center Under Contract No. HHSA29020050038I TO1). Rockville, MD: Agency for
Healthcare Research and Quality December 2009. Available at:
http://effectivehealthcare.ahrq.gov/reports/final.cfm.
2. Lee TA, Wilke C, Joo M, Stroupe KT, Krishnan JA, Schumock GT, Pickard AS. Outcomes associated
with tiotropium use in chronic obstructive pulmonary disease patients. Effective Health Care Research
Report No. 15. (Prepared by Chicago-Area DEcIDE Center Under Contract No. HHSA29020050038I
TO4). Rockville, MD: Agency for Healthcare Research and Quality. December 2009. Available at:
http://effectivehealthcare.ahrq.gov/reports/final.cfm.
3. Schumock GT, Lee TA, Pickard AS, Lee WJ, Patel H, Dilokthornsakul P, Shoaibi A, Archdeacon P.
Alternative methods for health outcomes of interest validation. Silver Spring, MD: Food and Drug
Administration, Sentinel Initiative, Mini-Sentinel Program. Available at
http://www.minisentinel.org/methods/outcome_validation/details.aspx?ID=105. Published August 31,
2013. Last accessed September 25, 2013.
4. INVITED PRESENTATIONS
A. Contributed Workshops, Training Courses, Symposia
1. Lee TA, Hollingworth W, Kind P. “Can the SF-36 be used in calculating QALYs?” Contributed
Workshop Presentation, International Society for Pharmacoeconomics and Outcomes Research, 8th
Annual International Meeting, Crystal City, VA, May 2003.
2. Sullivan SD, Lee TA. “Evaluating clinical and economic evidence for drug purchasing and formulary
considerations.” VA Medication Advisory Panel Committee Meeting, Chicago, IL, September 2004.
3. Buist AS, Padila RP, Menezes AM, Vollmer W, Lee TA, Burney P. “Measuring COPD prevalence:
two models for international collaboration.” 2005 ATS International Conference, San Diego, CA, May
2005.
Lee TA, Page 19
Revised: January 2018
4. Sullivan SD, Lee TA. “VA PBM/MAP pharmacoeconomic training program.” VA Pharmacy Benefits
Management Annual Meeting, Washington, DC, September 2005.
5. Buist S, Lee TA, Fabbri L, Jones P. “New Insights into the worldwide burden of COPD.” 2006
European Respiratory Society Congress, Munich, Germany, September 2006.
6. Au D, Doherty DE, Enright PL, Jones PW, Buist AS, Diette GB, Lee TA. “COPD Detection and Basis
for Treatment.” 2007 American Thoracic Society International Conference, San Francisco, CA, May
2007.
7. Bosworth H, Kiefe C, Lee TA, Weinberger M. “Managing Complexity in Chronic Care within the
Largest Integrated Health System in the U.S.: Current and Future Directions.” AcademyHealth Annual
Research Meeting 2007, Orlando, FL, June 2007.
8. Lee TA, Gaind S. “Complexity measurement in psychiatric care: a model for reimbursement.”
Canadian Psychiatric Association, Ottawa, ON, Canada, April 2008.
9. Enright PL, Tashkin DP, Lee TA, Furberg CD, Barr RG. “Are heart attacks a side effect of
anticholinergic inhalers?” CHEST 2008 International Meeting, Philadelphia, PA, October 2008.
10. Upson DJ, Lee TA. “Medication availability and access: issues of value and affordability.” 2009
American Thoracic Society International Conference, San Diego, CA, May 2009.
11. Busse WW, Reddel HK, Krishnan JA, Peden D, Wise RA, Cloutier M, Wilson SR, Lee TA, Wenzel
SE. “NHLBI and NAIAD Recommendations for Standardized Asthma Outcomes in Clinical
Research.” Scientific Symposium, 2011 American Thoracic Society International Conference, Denver,
CO, May 2011.
12. Lieu T, Albert RK, Krishnan JK, Goss CH, Bush A, Gerald JK, Lee TA. “Pro-Con Debate:
Comparative Effectiveness Research: Fool’s Gold or Promised Land.” Lee TA: Cost-effectiveness
from CER studies should be used to guide treatment decisions: CON. Symposium, 2012 American
Thoracic Society International Conference, San Francisco, CA, May 2012.
13. Lee TA. “Building and Running Decision Models in Microsoft Excel.” ISPOR UIC Student Chapter
Sponsored Event, Chicago, IL, January – March 2016.
B. Invited Lectures, Seminars
1. Evaluating new therapies for rheumatoid arthritis: Fitting Arava® and Enbrel® in the ‘Drug Purchaser
Guidelines’ Northwest Pharmacy Benefits Management Meeting, Seattle, WA, January 1999.
2. Factors influencing adherence with asthma treatments, Respiratory Nursing Conference, Chronic Lung
Disease: Strategies for Promoting Self-Management, Seattle, WA, March 2001.
3. Cost-effectiveness of triamcinolone versus fluticasone in adult asthmatics, College of Pharmacy,
University of Minnesota, Minneapolis, MN, March 2001.
4. Conducting a cost-effectiveness analysis in an equivalence trial, College of Pharmacy, University of
Southern California, Los Angeles, CA, April 2001.
5. Evaluation of cost-effectiveness in an equivalence trial: Azmacort HFA compared to Flovent, Hines VA
Hospital, Hines, IL, May 2001.
Lee TA, Page 20
Revised: January 2018
6. Issues in the evaluation of cost-effectiveness in a pragmatic equivalence trial: the case of Azmacort
versus Flovent, Northwestern University Medical School Seminar Series, Chicago, IL, November 2001.
7. Developing pharmacotherapeutic research in the VA, 2002 VA Health Services Research and
Development National Meeting, Washington, DC, February 2002.
8. The evolution of health economics and cost-effectiveness analysis, Contributed Session: Applying
Evidence-Based Medicine, Outcomes Research and Practice Guidelines in OEM, American College of
Occupational and Environmental Medicine’s 87th American Occupational Health Conference, Chicago,
IL, April 2002.
9. Developing pharmacoeconomic research, 2003 VA Health Services Research and Development National
Meeting, Washington, DC, February 2003.
10. Cost-effectiveness of VRE surveillance strategies in hospitalized patients, UIC College of Pharamcy
Center for Pharmacoeconomics Research Lecture and Seminar Series, Chicago, IL, April 2003.
11. The economic impact of chronic disability, Burden of COPD: Now and Beyond, 2003 AARC Satellite
Symposium, Orlando, FL, July 2003.
12. Economic costs and modeling in COPD, Research Workshop on the Global Burden of COPD,
Vancouver, BC, Canada, October 2004.
13. COPD Modeling, Improving survival in COPD – assessing the value of life-saving therapy, Rome, Italy,
November 2005.
14. Pharmacoepidemiology: Medication Use as Key Health Behavior and Complicated Confounder,
Biomarkers of Social and Health Behavior: Social Influences and Biological Processes, Chicago
Conference on Biomarker Collection in Population-Based Health Research, Chicago, IL, June 2006.
15. Breathe easier: using evidence to improve outcomes for patients with COPD, Regional Symposium,
Milwaukee, WI, November 2006.
16. Costs and cost-effectiveness analysis in pulmonary and critical care medicine, Sunrise Seminar,
American Thoracic Society 2007 International Conference, San Francisco, CA, May 2007.
17. Patients with multiple chronic conditions – healthcare system impact and opportunities for improving
care, Canadian Psychiatric Association, Ottawa, ON, Canada, April 2008.
18. Comparative Effectiveness and the Chicago-area DEcIDE Center, Roundtable Discussion (with Glen
Schumock), Society for Epidemiology Research 41st Annual Meeting, Chicago, IL, June 2008.
19. Epidemiology of multiple chronic conditions and elderly patients with COPD, CONCERT Consensus
Conference, San Diego, CA, May 2009.
20. Comparative effectiveness research in COPD, Meet the Professor Seminar, American Thoracic Society
2010 International Conference, New Orleans, LA, May 2010.
21. Comparative effectiveness research. CCTS 3-Day Summer Program in Clinical and Translational
Research, Chicago, IL, July 2010.
Lee TA, Page 21
Revised: January 2018
22. Safety of long-acting beta-agonists in patients with respiratory disease. 2011 Illinois Society for
Respiratory Care Conference and Exposition, Oak Brook, IL, June 2011.
23. Research at the crossroads of pharmacoepidemiology and pharmacoeconomics: outcomes of
comparative effectiveness research. 6th Annual Midwest Consortium Conference, Chicago, IL, July
2011.
24. Comparative effectiveness research. CCTS 3-Day Summer Program in Clinical and Translational
Research, Chicago, IL, July 2011.
25. Exposures/Interventions. DEcIDE Business Meeting, AHRQ 2011 Annual Conference, Bethesda, MD,
September 2011.
26. Health economics and patient health outcomes research (HEOR). The International Publication Planning
Association 2012 Midwest Meeting, Chicago, IL July 2012.
27. Comparative effectiveness research. CCTS 3-Day Summer Program in Clinical and Translational
Research, Chicago, IL, July 2012.
28. Advancing the quality and relevance of comparative effectiveness research. ISPOR CRC and AMCP
Midwest Affiliate 4th Annual Day of Education, Chicago, IL November 2012.
29. Pragmatic considerations in publication planning when partnering with academic investigators: the case
of outcomes research. The International Publication Planning Association 2013 Annual Meeting, Los
Angeles, CA February 2013.
30. Comparative effectiveness research. CCTS 3-Day Summer Program in Clinical and Translational
Research, Chicago, IL, July 2013.
31. Comparative effectiveness research. CCTS 3-Day Summer Program in Clinical and Translational
Research, Chicago, IL, July 2014.
32. Does improving quality stretch the healthcare dollar? COPD9USA, Chicago, IL June 2015.
33. What is CARMA and what can it do for you? IMEDS Community Call Webinar , June 2016.
34. Staying up-to-date on methods in drug safety: CARMIC insight. Learning from Electronic Data to
Advance Health and Health Care, 2nd Seattle Symposium on Health Care Data and Analytics, Seattle,
WA, October 2016.
35. Illinois PDMP Evaluation Activities, CDC Prevention for States and Data-Driven Prevention Initative
In-Person Meeting, Atlanta, GA, May 2017.
36. Value-based purchasing: theory and practice. Managing the price of pharmaceutical therapies for chronic
lung diseases in the United States, ATS Workshop, Washington, DC, May 2017.
5. RESEARCH PRESENTATIONS
1. Lee TA, Larson LN. “Evaluating the Use and the Quality of Pharmacy Drive-up Services” Poster
Presentation, American Pharmaceutical Association 1998 Annual Meeting, Miami Beach, FL, March
1998.
Lee TA, Page 22
Revised: January 2018
2. Lee TA, Ramsey SD, Neil NJ, Patrick DL, Klastorin TD, Stergachis A, Sullivan SD. “Developing a
Task-based Instrument to Measure Migraine-Related Productivity” Poster Presentation, International
Society for Pharmacoeconomics and Outcomes Research 3rd Annual Meeting, Philadelphia, PA, May
1998. Value Health 1998; 1(1): 82-83.
3. Sullivan SD, Schulz R, Lessler D, Weiss K, Ramsdell J, Lim J, Lee TA, Blough DK, Malone D,
Johnson ES. “Outcomes of Treatment with Inhaled Triamcinolone Acetonide after Twelve Months in
Moderate Adult Asthma: Clinical Results from the ACET-1 Cost-Effectiveness Study” Poster
Discussion Section, American Thoracic Society 1999 International Conference, San Diego, CA, April
1999.
4. Lee TA, Sullivan SD, Blough DK, Weiss K, Lim J, Ramsdell J. “Comparison of Outcome Measures in
a Randomized Trial of Inhaled Triamcinolone Acetonide in Adult Asthmatics” Poster Discussion
Section, American Thoracic Society 1999 International Conference, San Diego, CA, April 1999.
5. Lee TA, Sullivan SD, Ramsey SD, Steger P, Williamson T, Pliel A. “Economic Evaluation of
Systemic Treatments for CMV Retinitis in Persons with AIDS in Switzerland” Poster Presentation,
International Society for Pharmacoeconomics and Outcomes Research 4th Annual Meeting, Crystal
City, VA, May 1999. Value Health. 1999; 2(3): 183.
6. Lee TA, Sullivan SD. “The Effect of Order of Administration of Generic and Disease Specific Health
Status Questionnaires” Talking Poster Presentation, International Society for Pharmacoeconomics and
Outcomes Research 4th Annual Meeting, Crystal City, VA, May 1999. Value Health. 1999; 2(3): 158.
7. Bryant-Comstock L, Mather D, Lee T, Keck P, Li H, Sullivan S. “Treatment of bipolar depression:
clinical and economic outcomes.” Poster Presentation, American Psychiatric Association, 2000 Annual
Meeting, Chicago, IL, May 2000.
8. Murphy MP, Lee TA, Sullivan SD, Yeuh B. “Psychiatric disease in adults diagnosed with chronic
rhinosinusitis.” Podium Presentation, American Academy of Otolaryngology, 2000 Annual Meeting,
Washington, DC, September 2000.
9. Lee TA, McLaughlin T, Sullivan SD, Stanford R. “Asthma costs in managed care patients.” Poster
Presentation, American Academy of Family Physicians, 2001 Scientific Assembly, Atlanta, GA,
October 2001.
10. Lee TA, Sullivan SD, Weiss KB, Georges G. “Comparison of the effectiveness of inhaled
triamcinolone acetonide HFA to inhaled fluticasone propionate CFC in adult asthmatics in a 12-month
pragmatic trial.” Poster Presentation, American Thoracic Society 2002 International Conference,
Atlanta, GA, May 2002.
11. Lee TA, Sullivan SD, Weiss KB, Georges G. “Comparison of the cost-effectiveness of inhaled
triamcinolone acetonide HFA to inhaled fluticasone propionate CFC in adult asthmatics in a 12-month
pragmatic trial.” Poster Presentation, American Thoracic Society 2002 International Conference,
Atlanta, GA, May 2002.
12. Lee TA, Hollingworth W, Sullivan SD. “Directly elicited preferences compared to preferences derived
from the SF-36 in adult asthmatics.” Podium Presentation, International Society for
Pharmacoeconomics and Outcomes Research, 7th Annual International Meeting, Crystal City, VA, May
2002. Value Health. 2002; 5(3): 134-5.
Lee TA, Page 23
Revised: January 2018
13. Lee TA, Stroupe KT, Hacek D, Petersen L. “Evaluation of the cost-effectiveness of three vancomycin-
resistant enterococci surveillance strategies in hospitalized patients.” Poster Presentation, Infectious
Diseases Society of America, 40th Annual Meeting, Chicago, IL, October 2002.
14. Lee TA, Veenstra DL, Iloeje UH, Sullivan SD. “Direct medical costs associated with Hepatitis B virus
infection in the United States.” Poster Presentation, International Society for Pharmacoeconomics and
Outcomes Research, 8th Annual International Meeting, Crystal City, VA, May 2003.
15. Lee TA, Raymundo AL, Kim SS, Strauss M, Sullivan SD. “How does an 11-point pain scale relate to
preference estimates in patients with chronic pain and can it be used to predict preferences?” Poster
Presentation, International Society for Pharmacoeconomics and Outcomes Research, 8th Annual
International Meeting, Crystal City, VA, May 2003.
16. Marceille JR, Goins JA, Soni R, Biery JC, Lee TA. “Incidence of congestive heart failure-related
interventions in patients receiving rosiglitazone and insulin.” Poster Presentation, American College of
Clinical Pharmacy, 2003 Annual Meeting, Atlanta, GA, November 2003.
17. Lee TA, Bartle B, Xu J, Davis KJ, Weiss KB. “The association between inhaled corticosteroid use and
fractures in veterans with chronic obstructive pulmonary disease.” Poster Presentation, CHEST 03,
Orlando, FL, October 2003. Chest 2003; 124(4): 166S.
18. Lee TA, Xu J, Weiss KB. “Do follow-up physician visits impact the risk of repeat emergency
department visits in patients with COPD?” Poster Presentation, US COPD Coalition, National COPD
Conference, November 2003.
19. Lee TA, Bartle B, Xu J, Davis KJ, Weiss KB. “The risk of fractures associated with inhaled
corticosteroid use in patients with COPD.” Oral & Poster Presentation, US COPD Coalition, National
COPD Conference, November 2003.
20. Sullivan SD, Lee TA, Blough D, Finkelstein J, Lozano P, Inui T, Carey V, Wagner E, Fuhlbrigge A,
Weiss K. “Cost-effectiveness of Physician Peer Leader Education and Practice-based Redesign in
Managed Care: The Pediatric Asthma Care PORT-II Trial.” Oral Presentation, American Academy of
Allergy, Asthma and Immunology (AAAAI), 60th AAAAI Annual Meeting, March 2004. JACI 2004;
113(2 Suppl): S339.
21. Witt WP, Lee TA, Xu J, Baker DW, Weiss KB. “The mental health impact of living with a spouse with
chronic obstructive pulmonary disease.” Poster Presentation, Society of General Internal Medicine,
2004 Annual Meeting, May 2004.
22. Bednar MM, Wolozin B, Weiss KB, Lee TA. “Increased risk of Alzheimer’s disease diagnosis
following coronary artery bypass graft surgery compared to precutaneous transluminal coronary
angioplasty.” Poster Presentation, 9th Annual International Conference on Alzheimer’s Disease and
Related Disorders, July 2004.
23. Xu J, Lee TA, Witt WP, Durazo-Arvizu R. “Emergency department visits among COPD patients: an
example of repeat recurrent event analysis.” Oral Presentation, American Statistical Association 2004
Joint Statistical Meetings, August 2004.
24. Lee TA, Xu J, Weaver F, Weiss KB. “Risk of pneumonia-related hospitalizations in patients with
chronic lung disease.” Poster Presentation, VA Health Services Research and Development 2005
National Meeting, Baltimore, MD, February 2005.
Lee TA, Page 24
Revised: January 2018
25. Lee TA, Bartle B, Weiss KB. “Characterizing COPD exacerbation patterns in the VA healthcare
system.” Poster Presentation, VA Health Services Research and Development 2005 National Meeting,
Baltimore, MD, February 2005.
26. Smith BM, Stroupe KT, Lee TA, Durazo-Arvizu R, Cao L, Nydam T. “The impact of co-payment
change on discontinuation of VA pharmacy use.” Poster Presentation, VA Health Services Research
and Development 2005 National Meeting, Baltimore, MD, February 2005.
27. Stroupe KT, Smith BM, Lee TA, Durazo-Arvizu R, Cao L, Nydam T. “Medication copay increase and
medication acquisition from the VA.” Poster Presentation, VA Health Services Research and
Development 2005 National Meeting, Baltimore, MD, February 2005.
28. Lee TA, Bartle B, Weiss KB. “Characterizing COPD exacerbation patterns in the VA healthcare
system.” Poster Presentation, 2005 American Thoracic Society International Conference, San Diego,
CA, May 2005.
29. Lee TA, Bartle B, Weiss KB. “Patterns of Respiratory Medication Use in a VA COPD Cohort, 1999-
2002.” Poster Presentation, 2005 American Thoracic Society International Conference, San Diego, CA,
May 2005.
30. Lee TA, Xu J, Weaver F, Weiss KB. “Risk of Pneumonia-Related Hospitalizations in Patients with
Chronic Lung Disease.” Poster Presentation, 2005 American Thoracic Society International
Conference, San Diego, CA, May 2005.
31. Lee TA, Bartle B, Weiss KB. “Health System Variation in COPD Exacerbation Rates.” Poster
Presentation, 2005 American Thoracic Society International Conference, San Diego, CA, May 2005.
32. Lee TA, Bartle B, Weiss KB. “Spirometry Use in Clinical Practice in Patients with COPD.” Poster
Presentation, 2005 American Thoracic Society International Conference, San Diego, CA, May 2005.
33. Lee TA, Fuhlbrigge AL, Finkelstein JA, Sullivan SD, Lozano P, Carey V, Inui TS, Weiss KB.
“Agreement between Caregiver Reported Healthcare Utilization and Administrative Data for Children
with Asthma” Poster Presentation, 2005 American Thoracic Society International Conference, San
Diego, CA, May 2005.
34. Lee TA, Bartle B, McLaughlin T, Dirani R. “Adherence to respiratory medications in VA patients with
chronic lung disease.” Poster Presentation, International Society for Pharmacoeconomics and
Outcomes Research, 10th Annual International Meeting, Washington, DC, May 2005.
35. Grim S, Cannon J, Lee TA, Crank C, Patel G, Proia L, Labuszewski L, Mullane K, Jancel T, Clark N.
“Utilization of newer antifungals in a large metropolitan setting.” Poster Presesntation, Focus on
Fungal Infections 16, Las Vegas, NV, March 2006.
36. Scheetz MH, Lee TA, Noskin GA, Postelnick MJ, Bolon MK. “A cost-effectiveness analysis of an
antimicrobial utilization team on blood stream infections.” Poster Presentation, Society for Healthcare
Epidemiology of America (SHEA) 16th Annual Meeting, Chicago, IL, March 2006.
37. Venkatesh A, Lee TA, Barnard C, Noskin GA. “Adverse events among hospitalized patients
significantly increase costs.” Poster Presentation, Society for Healthcare Epidemiology of America 16th
Annual Meeting, Chicago, IL, March 2006.
Lee TA, Page 25
Revised: January 2018
38. Lee TA, Sullivan SD, Buist AS, Vollmer W, Weiss KB. “Estimating the future economic burden of
COPD.” Poster Presentation, 2006 American Thoracic Society International Conference, San Diego,
CA, May 2006.
39. Jordan N, Lee TA, Valenstein M, Weiss KB. “Factors associated with evidence-based depression
treatment for persons with COPD and depression.” Poster Presentation, 2006 American Thoracic
Society International Conference, San Diego, CA, May 2006.
40. Lee TA, Pickard AS, Bartle B, Weiss KB. “Prescription for longer life: a diagnosis of osteoarthritis?”
Poster Presentation, International Society for Pharmacoeconomics and Outcomes Research, 11th
Annual International Meeting, Philadelphia, PA, May 2006.
41. Weiss KB, Lee TA, Sullivan SD, Vollmer W, Buist AS. “Health status comparison of patients with
COPD throughout the world: the BOLD Initiative.” Poster Presentation, 2006 European Respiratory
Society Congress, Munich, Germany, September 2006.
42. Grim S, Gupta S, Holloway M, Lee TA, Paek J, Janda W, Clark N. “Candida Bloodstream Infections
(CBSI) at a University Hospital 2001-2004.” Poster Presentation, Infectious Diseases Society of
America, 44th Annual Meeting, Toronto, ON, October 2006.
43. Lee TA, Sin DD, Sullivan SD. “Cost-effectiveness of inhaled corticosteroids in COPD: results from
the BOLD economic model using ISEEC results.” Poster Presentation, CHEST 2006, Salt Lake City,
UT, October 2006. Chest 130(4): 179S.
44. Lee TA, Gao CY, Walter B, O’Connor GT, Sullivan SD, Buist AS, Weiss KB. “Rate of disease
progression in patients with COPD in the Framingham Heart Study cohort.” Slide Presentation,
CHEST 2006, Salt Lake City, UT, October 2006. Chest 130(4): 97S.
45. Ogale SS, Lee TA, Sullivan SD. “The risk of cardiovascular events associated with inhaled long-acting
beta-2-adrenoreceptor agonists in patients with chronic obstructive pulmonary disease.” Slide
Presentation, CHEST 2006, Salt Lake City, UT, October 2006. Chest 130(4): 121-S-122S.
46. Murthy K, Grobman WA, Lee TA, Holl JL. “Medical malpractice pressures for obstetrician-
gynecologists are associated with late preterm induction in Illinois.” Poster Presentation, 2007 Pediatric
Academic Societies’ Annual Meeting, Toronto, Canada, May 2007.
47. Murthy K, Grobman WA, Lee TA, Holl JL. “The effect of medical malpractice pressures for
obstetricians on term induction rates in Illinois.” Poster Presentation, 2007 Pediatric Academic
Societies’ Annual Meeting, Toronto, Canada, May 2007.
48. Murthy K, Grobman WA, Lee TA, Holl JL. “Racial disparities in term and post-term induction rates in
Illinois.” Podium Presentation, 2007 Pediatric Academic Societies’ Annual Meeting, Toronto, Canada,
May 2007.
49. Lee TA, Pickard AS, Bartle B, Schumock GT, Weiss KB. “Increased risk of mortality associated with
use of ipratropium and theophylline in COPD patients.” Poster Presentation, 2007 American Thoracic
Society International Conference, San Francisco, CA, May 2007.
50. Lee TA, Pickard AS, Bartle B, Schumock GT, Weiss KB. “Outcomes associated with theophylline use
in COPD patients.” Poster Presentation, 2007 American Thoracic Society International Conference,
San Francisco, CA, May 2007.
Lee TA, Page 26
Revised: January 2018
51. Lee TA, Gislason T, Sullivan SD, Benediktsdottir B, Gudmundsson G, Buist AS, Weiss KB. “Future
economic burden of COPD in Iceland: results from the BOLD initiative.” Poster Presentation, 2007
American Thoracic Society International Conference, San Francisco, CA, May 2007.
52. Ogale SS, Lee TA, Au DH, Boudreau DM, Sullivan SD. “Cardiovascular outcomes associated with
anticholinergic medications.” Poster Presentation, 2007 American Thoracic Society International
Conference, San Francisco, CA, May 2007.
53. Ogale SS, Lee TA, Au DH, Boudreau DM, Sullivan SD. “Long-acting beta2-agonists and all-cause
mortality in COPD.” Poster Presentation, 2007 American Thoracic Society International Conference,
San Francisco, CA, May 2007.
54. Valenstein M, Kavanagh J, Ganoczy D, Lee T, Smelson D, Jensen A. “The Impact of a Pharmacy-
Based Intervention on Antipsychotic Adherence Among Patients with Serious Mental Illness.”
AcademyHealth Annual Research Meeting, Orlando, FL, June 2007.
55. Cannon JP, Clark NM, Lee T, Setlak P, Grim SA. The incidence of carbapenem (CBP)-related
seizures: a meta-analysis. American College of Clinical Pharmacy Annual Meeting, Denver, CO,
October 2007.
56. Lee TA, Pickard AS, Bartle B, Weiss KB. “Medication Safety in COPD Patients: The Risk of
Respiratory and Cardiovascular Deaths Associated with Treatment in Veterans with COPD.” Oral
Presentation, VA Health Service Research and Development 2008 National Meeting, Baltimore, MD,
February 2008.
57. Lee TA, Ogale SS, Sullivan SD, Au D. “Risk of All-Cause Mortality Associated with Long-Acting
Beta-Agonist use in Veterans with COPD.” Oral Presentation, VA Health Service Research and
Development 2008 National Meeting, Baltimore, MD, February 2008.
58. Lee TA, Tan W, Fitzgerald M, Sin D, Marra C, Weiss KB, Sullivan SD. “Future Economic Burden of
COPD in Canada: Results from the BOLD Initiative.” Poster Presentation, 2008 American Thoracic
Society International Conference, Toronto, ON, May 2008.
59. Lee TA, Pickard AS, Bartle B, Weiss KB. “COPD Medication Safety: Risk of Respiratory and
Cardiovascular Deaths Associated with Treatment.” Poster Presentation, 2008 American Thoracic
Society International Conference, Toronto, ON, May 2008.
60. Lee TA, Wilke CT, Joo M, Stroupe KT, Krishnan JA, Schumock GT, Pickard AS. “Comparative
effectiveness of ipratropium in COPD patients.” Poster Presentation, International Society for
Pharmacoeconomics and Outcomes Research, 14th Annual International Meeting, Orlando, FL, May
2009.
61. Chang Y, Lee TA. “The economic burden of chronic obstructive pulmonary disease due to smoking.”
Poster Presentation, International Society for Pharmacoeconomics and Outcomes Research, 14th
Annual International Meeting, Orlando, FL, May 2009.
62. Bautista A, Stein BD, Lee TA, Meltzer DO, DiDomenico R, Krishnan JA, Schumock GT. “Specificity
of administrative data for identifying heart failure patients for hospital quality performance initiatives.”
Poster Presentation, International Society for Pharmacoeconomics and Outcomes Research, 14th
Annual International Meeting, Orlando, FL, May 2009.
Lee TA, Page 27
Revised: January 2018
63. Lee TA, Wilke CT, Joo M, Stroupe KT, Krishnan JA, Schumock GT, Pickard AS. “Outcomes
associated with tiotropium use in COPD patients.” Podium Presentation, International Society for
Pharmacoeconomics and Outcomes Research, 14th Annual International Meeting, Orlando, FL, May
2009.
64. Joo MJ, Au DH, Fitzgibbon ML, Lee TA. “Determinants of Spirometry Use and Accuracy of COPD in
Primary Care.” Poster Presentation, 2010 American Thoracic Society International Conference, New
Orleans, LA, May 2010.
65. Ly V, Brehm R, Cohen M, Kaplow D, Lee TA, Cutaia M. “Development of a Long-Term Oxygen
Therapy Registry to Study Practice Variability Within a Regional VA Health Care System (VISN3).”
Poster Presentation, 2010 American Thoracic Society International Conference, New Orleans, LA,
May 2010.
66. Lee TA, Joo MJ, Krishnan JA, Wilke CT, Schumock GT, Pickard AS. “Risk of Stroke Associated with
Ipratropium and Tiotropium Use in Patients with COPD.” Podium Presentation, 2010 American
Thoracic Society International Conference, New Orleans, LA, May 2010.
67. Brehm R. Ly V, Cohen M, Kaplow D, Lee TA, Cutaia M. “Survival Analysis of Patients on Long-
Term Oxygen Therapy Using an Electronic Record Registry Within a Regional VA Health Care
System.” Poster Presentation, 2010 American Thoracic Society International Conference, New Orleans,
LA, May 2010.
68. Stein BD, Bautista A, Charbeneau JT, Schumock GT, Lee TA, Lauderdale DS, Krishnan JA. “Validity
of ICD-9 code algorithms for identifying patients hospitalized for acute exacerbation of COPD.”
Podium Presentation, 2010 American Thoracic Society International Conference, New Orleans, LA,
May 2010.
69. Wilke CT, Lin FJ, Lee TA, Lambert BL, Joo MJ, Pickard AS. “Variability in measurement of
medication exposure in pharamcoepidemiologic studies of COPD.” Podium Presentation, 26th
International Conference on Pharmacoepidemiology and Therapeutic Risk Management, Brighton, UK,
August 2010.
70. Wilke CT, Lee TA, Lambert BL, Joo MJ, Pickard AS. “Sensitivity of Hazard Estimates to Exposure
Definition: A Simuluation Study.” Plenary Podium Presentation, 26th International Conference on
Pharmacoepidemiology and Therapeutic Risk Management, Brighton, UK, August 2010.
71. Joo MJ, Au DH, Fitzgibbon M, Lee TA. “Accuracy of physician diagnosis of COPD and determinants
of spirometry use.” Poster Presentation, 2011 American Thoracic Society International Conference,
Denver, CO, May 2011.
72. Lewis S, Au DH, Carson SS, Lee TA, Lindenauer PK, McBurnie MA, Mularski RA, Vollmer WM,
Krishnan JA. “Novel multi-institutional data infrastructure for comparative effectiveness research in
COPD (COPD DataHub).” Poster Presentation, 2011 American Thoracic Society International
Conference, Denver, CO, May 2011.
73. McKell JL, Allen NB, Daviglus ML, Joo MJ, Lee TA. “Variations in definitions of COPD across
ethnic groups using the NHANES database.” Poster Presentation, 2011 American Thoracic Society
International Conference, Denver, CO, May 2011.
Lee TA, Page 28
Revised: January 2018
74. Bunyan A, Lee TA, Au DH, Joo M. “Patient characteristics associated with misdiagnosis of COPD in
primary care.” Poster Presentation, 2012 American Thoracic Society International Conference, San
Francisco, CA, May 2012.
75. McKell JL, Conrad KJ, Joo M, Lee TA. “Reliability of a survey to determine primary care physicians
perspectives on the use of spirometry for the diagnosis of COPD.” Poster Presentation, 2012 American
Thoracic Society International Conference, San Francisco, CA, May 2012.
76. Lin FJ, Lee TA, Wong PS, Pickard AS. “Evaluation of changes in guidelines for medication
management of stable chronic obstructive pulmonary disease.” Poster Presentation, 2012 American
Thoracic Society International Conference, San Francisco, CA, May 2012.
77. Adimadhyam S, Schumock GT, Walton SM, Joo MJ, McKell JL, Lee TA. “Increased risk of
arrhythmias associated with inhaled anticholinergics in children, adolescents and young adults with
asthma.” Poster Presentation, 2012 American Thoracic Society International Conference, San
Francisco, CA, May 2012.
78. Sumino K, O’Brian KK, Bartle B, Au DH, Castro M, Lee TA. “Effects of co-existing chronic
conditions on mortality and morbidity in adult asthma.” Poster Presentation, 2012 American Thoracic
Society International Conference, San Francisco, CA, May 2012.
79. Joo M, Sharp L, Lee TA, Au DH, Fitzgibbon M. “Underutilization of spirometry in COPD: a
qualitative study of primary care physicians.” Poster Presentation, 2012 American Thoracic Society
International Conference, San Francisco, CA, May 2012.
80. Prieto-Centurion V, Rolle AG, Au DH, Carson SS, Henderson A, Lee TA, Lindenauer PK, McBurnie
M, Mularski RA, Naureckas ET, Vollmer W, Krishnan JA. “A comparison of three methods used to
identify patients with COPD.” Poster Presentation, 2013 American Thoracic Society International
Conference, Philadelphia, PA, May 2013.
81. Pickard AS, Lee TA, Lin FJ, Au DH, McBurnie MA, Carson SS, Lindenauer PK, Mularski RA,
Naureckas ET, Vollmer WM, Henderson AG, Krishnan JA. “Assessment of health-related quality of
life using EQ-5D-5L in patients with chronic obstructive pulmonary disease (COPD): experience in the
CONCERT cohort.” Poster Presentation, 2013 American Thoracic Society International Conference,
Philadelphia, PA, May 2013.
82. Pickard AS, Lin FJ, Lee TA, Sharma G, Au DH, McBurnie MA, Carson SS, Lindenauer PK, Mularski
RA, Naureckas ET, Vollmer WM, Henderson AG, Krishnan JA. “Evaluation of the functional
assessment of the chronic illness therapy (FACIT)-dyspnea short form in chronic obstructive
pulmonary disease.” Poster Presentation, 2013 American Thoracic Society International Conference,
Philadelphia, PA, May 2013.
83. Bunyan A, Lee TA, Au DH, Joo MJ. “Healthcare utilization associated with misdiagnosis of COPD in
primary care.” Poster Presentation, 2013 American Thoracic Society International Conference,
Philadelphia, PA, May 2013.
84. Pickard AS, Lee TA, Lin FJ, Au DH, McBurnie MA, Carson SS, Lindenauer PK, Mularski RA,
Naureckas ET, Vollmer WM, Henderson AG, Krishnan JA. “Measuring health using the patient
reported outcomes measurement information system (PROMIS-43) in chronic obstructive pulmonary
disease (COPD): experience in the CONCERT cohort.” Poster Presentation, 2013 American Thoracic
Society International Conference, Philadelphia, PA, May 2013.
Lee TA, Page 29
Revised: January 2018
85. Feemster LC, Ma J, McBurnie MA, Carson SS, Henderson AG, Lee TA, Lindenauer PK, Mularski
RA, Naureckas ET, Vollmer WM, Krishnan JK, Au DH. “The association of body mass index and
waist circumference with six-minute walk distance and symptoms among patients with COPD.” Poster
Presentation, 2013 American Thoracic Society International Conference, Philadelphia, PA, May 2013.
86. Joo MJ, Lee TA, Au DH, Fitzgibbon M. “Underutilization of spirometry in COPD: a survey of primary
care physicians.” Poster Presentation, 2013 American Thoracic Society International Conference,
Philadelphia, PA, May 2013.
87. Dilokthornsakul P, Chiakunapruk N, Lee TA. “Time-specific propensity score analysis for
observational study: a case study estimating the effectiveness of thiazolidinedione use.” Podium
Presentation, International Society for Pharmacoeconomics and Outcomes Research, 18th Annual
International Meeting, New Orleans, LA, May 2013.
88. Dilokthornsakul P, Schumock GT, Chiakunapruk N, Lee TA. “Estimating time-specific propensity
scores: a case study of the effectiveness of inhaled long-acting beta-agonists on asthma exacerbations.”
Poster Presentation, International Society for Pharmacoepidemiology, 29th International Conference on
Pharmacoepidemiology and Therapeutic Risk Management, Montreal, Canada, August 2013.
89. Dilokthornsakul P, Chiakunapruk N, Nimpitakpong P, Jeanpeerapong N, Jampachaisri K, Lee TA.
“Factors predicting medication oversupply in Thailand: a mixed model regression analysis.” Poster
Presentation, International Society for Pharmacoeconomics and Outcomes Research, 19th Annual
International Meeting, Montreal, Canada, May 2014.
90. Zueger PM, Lee TA. “Health care costs associated with acute cardiovascular events in a COPD patient
population.” Poster Presentation, International Society for Pharmacoeconomics and Outcomes
Research, 19th Annual International Meeting, Montreal, Canada, May 2014.
91. Dilokthornsakul P, Lee TA. “The association between tiotropium use and cardiac arrhythmia
hospitalization in patients with chronic obstructive pulmonary disease using a self-controlled case
series design.” Poster Presentation, International Society for Pharmacoeconomics and Outcomes
Research, 19th Annual International Meeting, Montreal, Canada, May 2014.
92. Ursan ID, Lee WJ, Lee TA. “Insulin or thiazolidinedione use and fracture risk in patients with chronic
obstructive pulmonary disease and diabetes mellitus.” Poster Presentation, International Society for
Pharmacoeconomics and Outcomes Research, 19th Annual International Meeting, Montreal, Canada,
May 2014.
93. Lee WJ, Lee TA. “Risk of acute angle-closure glaucoma associated with inhaled anticholinergic agents
in a COPD population.” Poster Presentation, International Society for Pharmacoeconomics and
Outcomes Research, 19th Annual International Meeting, Montreal, Canada, May 2014.
94. Stanford RH, Nag A, Mapel DW, Lee TA, Rosiello R, Schatz M, Vekeman F, Gauthier-Loiselle M,
Merrigan JFP, Duh MS. “Assessment of COPD exacerbation risk: utilizing health claims data to
develop and validate a risk equation.” Poster Presentation, 2014 American Thoracic Society
International Conference, San Diego, CA, May 2014.
95. Joo MJ, Au DH, Fitzgibbon M, Bunyan A, Vinicky M, Lee TA. “Comparative effectiveness of a
COPD assessment and management bundle versus usual care: baseline characteristics.” Poster
Presentation, 2014 American Thoracic Society International Conference, San Diego, CA, May 2014.
Lee TA, Page 30
Revised: January 2018
96. Sumino K, Castro M, O’Brian K, Bartle B, Au DH, Lee TA. “Impact of consolidation of combination
therapy in obstructive lung disease.” Poster Presentation, 2014 American Thoracic Society
International Conference, San Diego, CA, May 2014.
97. Stanford RH, Nag A, Mapel DW, Lee TA, Rosiello R, Schatz M, Vekeman F, Gauthier-Loiselle M,
Merrigan JFP, Duh MS. “Risk assessment of first severe COPD exacerbation using predictive models
based on health claims data.” Poster Presentation, 2014 American Thoracic Society International
Conference, San Diego, CA, May 2014.
98. Haas KP, Lee TA, Dilokthornsakul P, Joo MJ. “Survey to determine perspectives on the use of
spirometry in COPD: users versus non-users.” Poster Presentation, 2014 American Thoracic Society
International Conference, San Diego, CA, May 2014.
99. Dilokthornsakul P, Lee TA. “The association between pneumococcal vaccine and thrombocytopenia in
elderly patients with chronic obstructive pulmonary disease: a case-crossover study.” Poster
Presentation, 30th International Conference on Pharmacoepidemiology and Therapeutic Risk
Management, Taipei, Taiwan, October 2014.
100. Lee WJ, Lee TA, Pickard AS, Shoaibi A, Schumock GT. “Feasibility of alternative methods for health
outcomes of interest algorithm validation.” Poster Presentation, 30th International Conference on
Pharmacoepidemiology and Therapeutic Risk Management, Taipei, Taiwan, October 2014.
101. Patel VA, Walton SM, Galanter WL, Lee TA, Schumock G, Nutescu EA. The validity of algorithms
for identifying suspected and confirmed heparin-induced thrombocytopenia. Poster Presentation,
International Society for Pharmacoeconomics and Outcomes Research, 20th Annual International
Meeting, Philadelphia, PA, May 2015.
102. Patel VA, Galanter WL, Lee TA, Schumock G, Nutescu EA, Hohmann SF, Walton SM. Comparative
effectiveness and safety of argatroban and bivalirudin in patients with suspected heparin-induced
thrombocytopenia. Poster Presentation, International Society for Pharmacoeconomics and Outcomes
Research, 20th Annual International Meeting, Philadelphia, PA, May 2015.
103. Xing S, Lee TA. Second Generation Antipsychotics and Diabetes Risk Among Children and Young
Adults 6-24 Years of Age. Podium Presentation, International Society for Pharmacoepidemiology,
Mid-Year Meeting, Baltimore, MD, April 2016.
104. Manzoor BS, Lee TA, Sharp L, Galanter WL, Walton SM, Nutescu EA. A higher percentage of newly
initiated direct oral anticoagulant users switch back to traditional therapy. Podium Presentation,
International Society for Pharmacoeconomics and Outcomes Research, 22nd Annual International
Meeting, Boston, MA, May 2017.
105. Manzoor BS, Walton SM, Lee TA, Sharp LK, Galanter WL, Nutescu EA. Real-world adherence and
persistence with direct oral anticoagulants in adults with atrial fibrillation. Poster Presentation, The
International Society on Thrombosis and Hemostatis Congress, Berlin, Germany, July 2017.
6. Research Support5,**
Active
Martin (PI) 12/17 – 11/18 $168,327
Gilead Sciences
5 Unless noted, funding amounts represent total costs ** Indicates total direct costs
Lee TA, Page 31
Revised: January 2018
IN-US-342-4530
Expanding Hepatitis C virus care and cure: national experience using a clinical pharmacist-driven model
Role: Co-Investigator
Touchette (PI) 11/17 – 6/18 $125,000
Institute for Clinical and Economic Review
Economic evaluation of erenumab in the prophylactic treatment of migraine
Role: Co-Investigator
Investigators: Touchette D, Lee TA, Walton S
Touchette (PI) 3/17 – 3/18 $125,000
Institute for Clinical and Economic Review
Institute for Clinical and Economic Review Consulting Contract
Role: Co-Investigator
Investigators: Touchette D, Lee TA, Pickard AS, Schumock GT, Walton S
Joo (PI) 9/16 – 7/19 $1,500,000
Agency for Healthcare Research and Quality
1R01HS024964-01
Reducing Diagnostic Error to Improve Patient Safety in COPD and Asthma (REDEFINE Study)
Role: Co-Investigator
Lee (PI) 9/15 – 9/19 $420,000
Centers for Disease Control
1U17CE002739-01
Evaluation plan for prescription drug overdose prevention for states: Illinois
Role: Principal Investigator
Daviglus (PI) 4/15 – 3/20
NHLBI
5T32HL125294-02
Training in CVD Epidemiology and Related Chronic Diseases in Minority Populations
Role: Mentor
Completed
Gerald (PI) 8/13 – 4/17 $3,155,975
NHLBI
1R18HL110858-01A1
The cost effectiveness of school-based supervised asthma therapy
Role: Co-Investigator
Investigators: Gerald LB, Gerald J, Lee TA
Lee (PI) 12/15 – 12/16 $60,000
IMEDS-Reagan Udall Foundation
UIC CPR Center for Annotating Research Methods and Analyses (CARMA): Focused on New Approaches
in Utilizing ‘Real World’ Data
Role: Principal Investigator
Boudreau (PI) 1/14 – 6/15 $46,572**
FDA
HHSF223200910006I
NDI plus linkage to the mini-sentinel distributed data network
Lee TA, Page 32
Revised: January 2018
Role: Co-Investigator
Lee (PI) 7/13 – 6/15 $184,953**
Astellas
Astellas-UIC fellowship in pharmacoepidemiology and pharmacovigilance
Role: PI
Schneeweiss (PI) 1/14 – 3/15 $18,112**
FDA
HHSF223200910006I
Analytic methods to assess the robustness of drug safety monitoring results
Role: Co-Investigator
Pickard (PI) 8/13 – 8/14 $35,454
ARIAD Pharmaceuticals, Inc
BCR-ABL1 mutations conferring treatment resistance
Role: Co-Investigator
Investigators: Pickard AS, Lee TA
Schumock (PI) 10/12 – 8/13 $205,200
FDA
HHSF22301008T-0009
Alternative methods for health outcomes of interest validation
Role: Co-Investigator
Investigators: Schumock GT, Lee TA, Pickard AS
Pizer (PI)
VA HSR&D 4/11 – 9/13 $658,603**
IIR 10-136
Comparative effectiveness of anti-diabetic medication alternatives for Veterans
Role: Co-Investigator
Investigators: Pizer S, Edelman D, Conlin P, Lee TA, Gellad W
Jordan (PI)
VA HSR&D 10/10 – 6/13 $216,800**
Depression care facility-level variation for persons with multimorbidity
Role: Co-Investigator
Investigators: Jordan N, Lee T, Sohn M, Valenstein M, Yano E
Evans (PI)
VA HSR&D 4/11 – 3/13 $219,399**
C. difficile outcomes and effectiveness of treatment strategies in SCI
Role: Co-Investigator
Investigators: Evans C, Smith B, Lee TA
Lee (co-PI)
NHLBI 9/09 – 8/12 $7,439,784
1RC2HL101618-01
CONCERT-Clinical Effectiveness Research (CONCERT-CER)
Role: Co-PI
Investigators: Krishnan J (co-PI), Au D (co-PI), Carson S (co-PI), Lee T (co-PI), Lindenauer P (co-PI),
McBurnie M (co-PI), Mularski R (co-PI), Henderson A, Naurekas E, Pickard A, Schumock G, Vollmer W
Lee TA, Page 33
Revised: January 2018
Hynes (PI)
VA HSR&D 5/09 – 4/12 $846,200**
IIR 08-354
Clinical guidelines for ESA use in cancer: impacts on clinical practice
Role: Co-Investigator
Investigators: Hynes D, Lee T, Stroupe K, Tarlov E
Hynes (PI)
VA HSR&D 8/03 – 5/11 $1,221,717**
IIR 03-196
Quality and costs of colon cancer care in VA and Medicare
Role: Co-Investigator
Investigators: Hynes D, Bennett C, Durazo-Arvizu R, Lee T, Sohn M, Tarlov E
Jordan (PI)
AHRQ 9/08 – 8/11 $249,796
R21HS017635-1
Effect of chronic illness complexity on evidence-based depression treatment
Role: Co-Investigator
Investigators: Jordan N, Lee T, Sohn M
Weiss (PI)
RWJ 12/07 – 12/10 $1,178,905
Characterizing costs and episodes of care
Role: Co-Investigator
Investigators: Weiss K, Lee T, Manheim L, Stroupe K
Hidalgo (PI)
DOD 10/08 – 9/10 $204,993
HHSP23320045013XI
Complex chronic care among Tricare beneficiaries: cost effective treatment strategies
Role: Project Lead Investigator
Investigators: Hidalgo J, Jordan N, Lee T, Sohn M, Stroupe K
Lee (PI)
VA HSR&D 7/06 – 12/10 $349,537**
IIR 05-293
NSAID Related Adverse Events: Evaluating Risk Using Clinical Information
Role: Principal Investigator
Investigators: Lee T, Mak E, Sohn M, Weiss K
Pickard (PI)
AHRQ 11/08 – 12/09 $275,948
HHSA290-2005-0038-I-TO4-WA2
Development of a multicenter prospective study to assess the effectiveness of treatment for COPD
Role: Project Lead Investigator
Investigators: Pickard A, Joo M, Krishnan J, Lee T, Schumock G
Pickard (PI)
AHRQ 8/07 – 12/08 $224,051
HHSA290-2005-0038-I-TO4-WA1
Lee TA, Page 34
Revised: January 2018
Comparative effectiveness of anticholinergic medications in patients with chronic obstructive pulmonary
disease (COPD)
Role: Project Lead Investigator
Investigators: Pickard A, Joo M, Krishnan J, Lee T, Schumock G, Stroupe K
Lee (PI)
VA HSR&D 10/04 – 9/07 $651,900**
IIR 03-307
Outcomes associated with salmeterol use in obstructive lung disease
Role: Principal Investigator
Investigators: Lee T, Weiss K
Pickard (PI)
EuroQol Group 1/07 – 12/07 $9,200
Quality of life according to the EQ-5D in asthma and COPD
Role: Co-Investigator
Investigators: Pickard A, Lee T
Lee (PI)
GlaxoSmithKline 12/06 – 11/07 $136,165
Assessment of the use and outcomes of antithrombotics following orthopedic surgery in the VA
Role: Principal Investigator
Investigators: Lee T, Pickard A
Schumock (PI)
AHRQ 10/05 – 9/06 $249,851
HHSA29020050038I
Outcomes of COPD Management
Role: Project Lead Investigator
Investigators: Schumock G, Lee T, Weiss K
Armstrong (PI)
VA HSR&D 1/03 – 12/06 $812,700**
IIR 20-059-2
Dermal Thermometry and Self-Care in High Risk Diabetic Patients
Role: Co-Investigator
Investigators: Armstrong D, Lavery L, Lee T, Wendel C
Valenstein (PI)
VA HSR&D 3/04 – 10/06 $153,019**
IIR 01-074
Improving antipsychotic adherence among patients with serious mental illness
Role: Co-Investigator / Site PI
Investigators: Valenstein M, Blow F, Dalack GW, Grabowski J, Lee T, Poddig B, Reilly P, Ronis D,
Smelson D
Sheilds (PI)
DoD 9/04 – 3/06 $330,873
Consortium on complex chronic illness: improving health care experiences and quality of care among
military health system beneficiaries living with chronic illness
Role: Co-Investigator
Investigators: Sheilds A, Vogeli C, Gibson T, Lee T, Weiss K, Hidalgo J, Marder W, Blumenthal D
Lee TA, Page 35
Revised: January 2018
Walton (PI)
Takeda 10/03 – 9/05 $107,000
Assessment of the risk of large and small vessel disease in patients with type 2 diabetes
Role: Co-Investigator
Investigators: Walton S, Lee T, Pickard A
Lee (PI)
Pfizer 9/04 – 8/05 $106,305
Population-based COPD progression estimates
Role: Principal Investigator
Investigators: Lee T, Sullivan S, Weiss K
Lee (PI)
NDC Health 9/04 – 8/05 $125,551
Medication adherence in patients with respiratory disease
Role: Principal Investigator
Investigators: Lee T, McLaughlin T
Stroupe (PI)
VA HSR&D 7/03 – 6/05 $402,960**
ECI 02-220
Effect of increased co-payment on pharmacy use in the VA
Role: Co-Investigator
Investigators: Stroupe K, Smith B, Cunningham F, Hynes D, Lee T, Weiss K
Lee (PI)
AAMC-CDC 10/02 – 9/04 $171,346
MM-0204-03/03
Pneumococcal Pneumonia in VA Patients with Lung Disease
Role: Principal Investigator
Investigators: Lee T, Weaver F, Weiss K
Weiss (PI)
AHRQ 9/02 – 9/04 $497,611
Outcomes assessment in pediatric asthma
Role: Co-Investigator
Investigators: Weiss K, Lozano P, Fuhlbrigge A, Finkelstein J, Inui T, Sullivan SD, Lee T
Lee (PI)
AstraZeneca 7/03 – 6/04 $63,199
Examining variations in care and exacerbations in patients with COPD
Role: Principal Investigator
Investigators: Lee T, Weiss K
Lee (PI)
Alliance (Boehringer-Ingelheim – Pfizer) 3/03 – 8/04 $91,704
Characterizing the Burden of Chronic Obstructive Pulmonary Disease
Role: Principal Investigator
Investigators: Lee T, Weiss K, Van De Graaff W
Weiss (PI)
Lee TA, Page 36
Revised: January 2018
MCR Vision 6/02 – 9/04 $169,175
Model of the current and future healthcare expenditures for chronic obstructive pulmonary disease
Role: Co-Investigator
Investigators: Weiss K, Lee T, Sullivan S
Lee (PI)
VA HSR&D 9/03 – 12/03 $9,360
LIP 42.078
Comparison of multiple proxy and patient perspectives on quality of life
Role: Principal Investigator
Investigators: Lee T, Pickard A
Lee (PI)
Pfizer 7/03 – 6/04 $20,808
Assessment of the association between the development of Alzheimer’s disease and exposure to general
anesthesia
Role: Principal Investigator
Investigators: Lee T, Weiss K, Wolozin B
Lee (PI)
GlaxoSmithKline 8/02 – 6/03 $86,586
Inhaled corticosteroid use and the risk of fractures in COPD patients in the VA
Role: Principal Investigator
Investigators: Lee T, Weiss K
Lee (PI)
VA HSR&D 6/02 – 9/02 $8,000**
LIP 42.066
Development of an algorithm to identify community acquired pneumococcal pneumonia using pharmacy
and outpatient data
Role: Principal Investigator
Investigators: Lee T, Weiss K, Weaver F
Lee (PI)
GlaxoSmithKline 1/03 – 6/03 $1,000
Synopsis of the Functional Independence Measure
Role: Principal Investigator
Investigators: Lee T
Lee (PI)
GlaxoSmithKline 1/03 – 6/03 $2,000
Evaluation of selected preference, health status, and function assessment instruments
Role: Principal Investigator
Investigators: Lee T
Lee (PI)
American Pharmaceutical Association 1/97 – 5/97 $1,000
Innovative Research Grant
Evaluating the Quality of Pharmacy Drive-Up Services
Role: Principal Investigator
Investigators: Lee T, Larson L
Lee TA, Page 37
Revised: January 2018
7. SERVICE
A. Memberships in Professional and Scientific Organizations and Societies
1995 – 2009 American Pharmaceutical Association
1997 – 2002 International Health Economics Association
1997 – present International Society for Pharmacoeconomics and Outcomes Research
1997 – 2002 American Association of Colleges of Pharmacy
1999 – 2003 Drug Information Association
1999 – 2003 Society for Medical Decision Making
2009 – present American Thoracic Society
2009 – 2014 Academy of Managed Care Pharmacy
B. Journals***
Reviewer Inquiry, Pharmacoeconomics, Quality of Life Research***, Journal of Clinical Outcomes
Management, Value in Health, Medical Care, Expert Opinion on Pharmacotherapy,
European Respiratory Journal, Medical Decision Making, Journal of COPD, Archives
of Internal Medicine, JAMA, Chest, Journal of General Internal Medicine,
Pharmacotherapy***, Thorax, Annals of Internal Medicine***, Journal of Aging***,
Annals ATS***, Canadian Medical Association Journal***, PLOS One***, BMC Health
Services Research***, Annals of Pharmacotherapy***
C. Committee Service
University / Institution Committee Service
1996 – 1997 Drake University, Academic Integrity Committee, Member
1997 University of Washington, Graduate Admissions Committee, Member
2007 – 2008 Institute for Healthcare Studies, Post-doctoral Fellowship Executive Committee, Member
2008 – 2011 Research and Development Committee, Hines VA Hospital, Member
2009 – present Corporate Research Data Warehouse Clinical Advisory Committee, Bioinformatics Core,
UIC Center for Clinical and Translational Sciences (CCTS) , Member
2009 – 2011 Center for Pharmacoecomonic Research Executive Committee, University of Illinois at
Chicago, Member
2010 Promotion guidance committee, Center for Management of Complex Chronic Care
(CMC3), Hines VA Hospital, Member
2010 Research Strategic Plan Development Committee, Hines VA Hospital, Member
2010 Grant Submission Process Improvement Committee, Center for Management of Complex
Chronic Care (CMC3), Hines VA Hospital, Member
2010 Faculty search committee, Rockford Pharmacy Administration Faculty Position, University
of Illinois at Chicago, Member
2010 – 2011 UIC Center for Clinical and Translational Sciences (CCTS) Comparative Effectiveness
Research Symposium / Workshop Planning Committee, Member
2010 – 2012 Chicago-area Clinical and Translational Sciences Awards Comparative Effectiveness
Research Strategic Planning Committee, University of Illinois at Chicago representative
(1 of 2 UIC members), Member
2013 – present Lon Larson Engaged Practitioner Award, Drake University, Selection Committee Member
2013 – present Educational Policy Committee, College of Pharmacy, University of Illinois at Chicago,
Committee Member
2017 – present Chancellor’s Intercollegiate Advisory Committee, University of Illinois at Chicago,
Committee Member
2017 Faculty search committee, Biopharmaceutical Sciences Department Head, University of
Illinois at Chicago, Member
*** Indicates reviewed for journal in last two years
Lee TA, Page 38
Revised: January 2018
2017 PSOP Promotion and Tenure Committee, College of Pharmacy, University of Illinois at
Chicago, Chair
Regional, National or International Committees
2002 VA HSR&D 2002 Annual Meeting Poster Awards Committee, Member
2002 AHRQ Evidence-based Medicine Report on Seasonal Allergies, Effect on Working
Populations, Peer reviewer
2002 JCAHO Disease-Specific Care Asthma Expert Panel, Panel Member
2002 – 2003 Integrating Economic Analysis into Cancer Clinical Trials Conference, Chicago, IL Co-
Chair
2003 Contributed Research Review Committee, ISPOR 8th Annual International Meeting
2003 – 2004 Medication Compliance Bibliography Working Group, ISPOR Medication Compliance
Special Interest Group
2003 – 2010 Salt Lake Informatics and Patient Safety Enhancement Program, Steering Committee
Member
2003 – 2011 VIReC Pharmacy Data Workgroup, Member
2006 – 2010 ATS Project Committee: How does lack of health insurance contribute to health disparities
for patients with lung disease and critical illness?, Member
2006 – 2007 ISPOR, 2007 Annual Meeting, Contributed Research Review Committee, Co-Chair
2007 ISPOR Chicago-region Chapter, Organizing Committee
2007 ISPOR Chicago-region Chapter, Director
2007 – 2011 Chicago-area DEcIDE, Steering Committee Member
2008 – 2013 Academy of Managed Care Pharmacy (AMCP) Format for Formulary Submissions
Executive Committee, Member
2008 – 2014 ISPOR, Bernie J. O’Brien New Investigator Award Committee, Member
2010 – 2012 Respiratory Measurement Advisory Panel, National Center for Quality Assurance, Member
2014 – present Respiratory Measurement Advisory Panel, National Center for Quality Assurance, Member
2015 – present Agency for Healthcare Research and Quality Healthcare (AHRQ) Horizon Scanning
System (HHSS), Expert Commenter
2016 – present VA Information Resource Center (VIReC) Pharmacy Information Technical Advisory
Group, Member
Scientific Merit Review Panels
2005 VA HSR&D Scientific Merit Review Board (SMRB), Chronic Disease Management and
Behavioral Processes Review Group, Ad hoc reviewer
2005 VA HSR&D Scientific Merit Review Board (SMRB), Quality Measurement and
Effectiveness Review Group, Ad hoc reviewer
2005 Michael Smith Foundation for Health Research, Career Awards, External reviewer
2005 – 2009 VA HSR&D Scientific Merit Review Board (SMRB), Chronic Diseases and Quality
Measurement & Effectiveness, Member
2007 AHRQ, Centers for Education and Research in Therapeutics Special Emphasis Panel
(CERTs SEP), Reviewer
2011 VA QUERI, Rapid Response Project Review Panel, Ad hoc reviewer
2011 VA QUERI, Implementation Service Directed Project Review Panel, Ad hoc reviewer
2011 NIH Neurological, Aging and Musculoskeletal Epidemiology (NAME) Study Section, Ad
hoc reviewer
2011 – 2012 NHLBI Ancillary Studies in Clinical Studies Special Emphasis Panel, Reviewer
2012 VA HSR&D Special CREATE Review, Chair
2013 NCI Special Emphasis Panel, Sensors and Mobile Devices for Health Monitoring SBIR,
Reviewer
2014 – 2015 AHRQ Healthcare Safety and Quality Improvement Research (HSQR) Study Section, Ad
hoc reviewer
Lee TA, Page 39
Revised: January 2018
D. Mentoring
Career Development Awards
Karna Murthy, MD, Children’s Hospital Research Career Development Award, Children’s Hospital. 2008 –
2011.
Min Joo, MD, University of Illinois at Chicago, NHLBI K-23, 1K23HL09446-01A1. 2009 – 2014.
Rahul Khare, MD, Northwestern University, AHRQ K-08, K08HS019005. 2010 – 2015.
Bharati Prasad, MD, University of Illinois at Chicago, University of Chicago/University of Illinois at
Chicago KM1 Career Development, NCI KM-1, KM1CA156717. 2011 – 2013.
Anna Porter, MD, University of Illinois at Chicago, University of Chicago/University of Illinois at Chicago
KM1 Career Development, NCI KM-1, KM1CA156717. 2011 – 2013.
Kaharu Sumino, MD, Washington University, Washington University School of Medicine Clinical Research
Training Center KM1 Comparative Effectiveness Research (CER) Career Development Program. 2012 –
2013.
Visiting Scholars
Piyameth Dilakthornsakul, PharmD, PhD Candidate, Naresuan Univeristy, Thailand. 2012 – 2013.
Fellows
Mehul Soni, PharmD, AstraZeneca Post-Doctoral Fellow, Institute for Health Services Research and Policy
Studies, Northwestern University. 2001 – 2002.
Min Joo, MD, Northwestern University Post-Doctoral T-32 Fellow, Institute for Healthcare Studies,
Northwestern University Feinberg School of Medicine. 2005 – 2007.
Rahul Khare, MD, Northwestern University Post-Doctoral T-32 Fellow, Institute for Healthcare Studies,
Northwestern University Feinberg School of Medicine. 2006 – 2008.
Yaojen Chang, PhD, Northwestern University Post-Doctoral T-32 Fellow, Institute for Healthcare Studies,
Northwestern University Feinberg School of Medicine. 2008 – 2009.
Rahul Khare, MD, Northwestern University Post-Doctoral F-32 Fellow, Northwestern University Feinberg
School of Medicine. 2009 – 2010.
Patrick Zueger, PharmD, Astellas-UIC Fellow in Pharmacovigilance and Pharmacoepidemiology,
University of Illinois at Chicago, Center for Pharmacoepidemiology and Pharmacoeconomic Research. 2013
– 2015.
Shan Xing, PharmD, NIMH Post-Doctoral F-31 Fellow, College of Pharmacy, University of Illinois at
Chicago. 2017.
Dissertation/Thesis Committees
Student Degree Dissertation/Thesis Title Program Year Role
Zhixaio Wang PhD Medication adherence and
its impact on health care
utilization in veterans with
Type II diabetes
Department of Pharmacy
Administration, College
of Pharmacy, University
of Illinois at Chicago
2006 Committee
Member
Lee TA, Page 40
Revised: January 2018
Student Degree Dissertation/Thesis Title Program Year Role
Sarika Ogale PhD Mortality and
cardiovascular outcomes
associated with
medications used in the
treatment of chronic
obstructive pulmonary
disease
Pharmaceutical
Outcomes Research and
Policy Program,
Department of
Pharmacy, University of
Washington
2006 Committee
Member
Caitlyn T. Wilke MS Comparison of utility
weighted and unweighted
HRQL measures: an
empirical study
Department of Pharmacy
Administration, College
of Pharmacy, University
of Illinois at Chicago
2007 Committee
Member
Eunmi Jung MS Medication use and
adherence prior to death in
patients with chronic
obstructive pulmonary
disease
Department of Pharmacy
Administration, College
of Pharmacy, University
of Illinois at Chicago
2007 Committee
Member
Caitlyn T. Wilke PhD Challenges and
consequences of
medication exposure
definitions in comparative
effectiveness research
Department of Pharmacy
Administration, College
of Pharmacy, University
of Illinois at Chicago
2010 Committee
Member
Sruthi
Adimadhyam
MS Risk of arrhythmias
associated with inhaled
anticholinergics in young
individuals with asthma
Department of Pharmacy
Administration, College
of Pharmacy, University
of Illinois at Chicago
2011 Committee
Member
Glen T.
Schumock
PhD Association between
leukotriene-modifying
agents and suicide in
patients with asthma
Department of
Epidemiology and
Biostatistics, School of
Public Health, University
of Illinois at Chicago
2012 Committee
Member
Fang-Ju Lin PhD Condition specific
applications for the
valuation of health
Department of Pharmacy
Systems, Outcomes and
Policy, College of
Pharmacy, University of
Illinois at Chicago
2013 Committee
Member
Garima Sharma MS Psychometric validation
of the FACIT-dyspnea
scale in COPD patients
Department of Pharmacy
Systems, Outcomes and
Policy, College of
Pharmacy, University of
Illinois at Chicago
2013 Committee
Member
Kun Peng MS The misdiagnosis of
COPD by spirometry in
the US
Department of Pharmacy
Systems, Outcomes and
Policy, College of
Pharmacy, University of
Illinois at Chicago
2014 Chair
Vardhaman
Patel
PhD Direct thrombin
inhibitors: use and
consequences in patients
with heparin-induced
thrombocytopenia
Department of Pharmacy
Systems, Outcomes and
Policy, College of
Pharmacy, University of
Illinois at Chicago
2015 Committee
Member
Lee TA, Page 41
Revised: January 2018
Student Degree Dissertation/Thesis Title Program Year Role
Piyameth
Dilokthornsakul
PhD Pharmacoepidemiology of
medication oversupply
and associated financial
burdens in Thailand
Faculty of
Pharmaceutical Sciences,
Naresuan University
2015 Committee
Member
Matthew
Monberg
PhD Pharmacoepidemiologic
evaluation of
erythropoietin stimulating
agents in head and neck
cancer
Division of
Epidemiology and
Biostatistics, School of
Public Health, University
of Illinois at Chicago
2016 Committee
Member
Kibum Kim PhD Insight into the use and
outcomes of anti-platelet
agents in patients with
acute coronary syndrome
Department of Pharmacy
Systems, Outcomes and
Policy, College of
Pharmacy, University of
Illinois at Chicago
2016 Committee
Member
Kristin Boulter MPH The association between
topiramate as a
prophylactic migraine
treatment and attention
deficit hyperactivity
disorder in a pediatric
population
Division of
Epidemiology and
Biostatistics, School of
Public Health, University
of Illinois at Chicago
2016 Capstone
Committee
Member
Wan-Ju Lee PhD Utilization and risk of
serious infection
associated with TNF-
alpha inhibitors in
children and young adults
Department of Pharmacy
Systems, Outcomes and
Policy, College of
Pharmacy, University of
Illinois at Chicago
2016 Committee
Member
Jennifer C.
Samp
PhD Outcomes of patients with
chronic obstructive
pulmonary disease treated
with combination of two
bronchodilators compared
to those treated with
combination long-acting
beta-2 agonist and inhaled
corticosteroid
Department of Pharmacy
Systems, Outcomes and
Policy, College of
Pharmacy, University of
Illinois at Chicago
2017 Chair
Shan Xing PhD Impact of second
generation antipsychotics
on diabetes outcomes
among patients with major
depressive disorder and
pre-existing diabetes
Department of Pharmacy
Systems, Outcomes and
Policy, College of
Pharmacy, University of
Illinois at Chicago
2017 Chair
Beenish
Manzoor
PhD Navigating safety of oral
anticoagulant use, from
precision medicine to
direct oral anticoagulants:
a mixed-methods
approach
Department of Pharmacy
Systems, Outcomes and
Policy, College of
Pharmacy, University of
Illinois at Chicago
2017 Committee
Member
Lee TA, Page 42
Revised: January 2018
Student Degree Dissertation/Thesis Title Program Year Role
Hari Patel Risk evaluation and
prediction of cardiac
events among
azithromycin users
Department of Pharmacy
Systems, Outcomes and
Policy, College of
Pharmacy, University of
Illinois at Chicago
In
Progress
Chair
Patrick Zueger Study of trends and
outcomes of prescription
medications ended during
hospice care (STOP
MED)
Department of Pharmacy
Systems, Outcomes and
Policy, College of
Pharmacy, University of
Illinois at Chicago
In
Progress
Chair
Deval Gor Antidiabetic drugs in
patients with chronic
kidney disease: trends,
adherence and economic
outcomes
Department of Pharmacy
Systems, Outcomes and
Policy, College of
Pharmacy, University of
Illinois at Chicago
In
Progress
Committee
Member
Rachel
Harrington
Department of Pharmacy
Systems, Outcomes and
Policy, College of
Pharmacy, University of
Illinois at Chicago
In
Progress
Chair
Ernest Law Department of Pharmacy
Systems, Outcomes and
Policy, College of
Pharmacy, University of
Illinois at Chicago
In
Progress
Committee
Member
Sruthi
Adimadhyam
Comparative safety and
effectiveness of sodium
glucose co-transporter-2
inhibitors in patients with
type 2 diabetes
Department of Pharmacy
Systems, Outcomes and
Policy, College of
Pharmacy, University of
Illinois at Chicago
In
Progress
Committee
Member
Inyoung Lee Department of Pharmacy
Systems, Outcomes and
Policy, College of
Pharmacy, University of
Illinois at Chicago
In
Progress
Chair
Graduate Student Dissertation Funding /Awards
Student Award Year(s)
Fang-Ju Lin Dean’s Scholar Fellowship 2012-2013
Wan-Ju Lee Dean’s Scholar Fellowship 2015-2016
Patrick Zueger Dean’s Scholar Fellowship 2016-2017
Patrick Zueger Paul D. Doolen Graduate Scholar for the Study of Aging 2016-2017
Beenish Manzoor Excellence in Research – Best Scientific Poster Award from
ISPE UIC Student Chapter; UIC Research Day
2017
Shan Xing Dean’s Scholar Fellowship 2017-2018
Shan Xing NIMH F31MH114465 2017-2018
Rachel Harrington R25 Cancer Education and Career Development Program
Pre-Doctoral Fellowship
2017-2018
Lee TA, Page 43
Revised: January 2018
E. Community Activities
2006 – 2009 Member, Oak Park Medical Reserve Corps, Oak Park, IL
2009 – 2013 T-ball Coach (boys and girls), Oak Park Youth Baseball / Softball, Oak Park, IL
2010 – 2012 Team Manager, Oak Park River Forest Strikers Soccer Club, Oak Park, IL
2012 – 2014 Team Manager, Chicago Edge Soccer Club, River Forest, IL
2013 – 2016 Boys Youth Basketball Coach, Ascension School, Oak Park, IL
2014 – 2017 Girls Softball Coach, Oak Park Youth Baseball / Softball, Oak Park, IL
2014 – present Board of Directors, Chicago Edge Soccer Club, River Forest, IL
8. ACTIVITY PROFILE
Research and scholarly activity 55%
Instructional activity 20%
University and public service 5%
Student advising / mentoring 10%
Faculty / K-award mentoring 5%
Administration 5%